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Polypharmacy is prevalent among most of the therapeutic regimens to treat patients. 
Approximately one third of adults in the United States take complementary and 
alternative medicines (CAM) (1). Interactions between these drugs may affect the 
pharmacological or adverse effects of each other and complicate the management of 
long-term drug therapies.  
 
Numerous drug interactions are observed with oral anticoagulant warfarin. The effects 
of warfarin are highly sensitive to the co-administered drugs. Warfarin therapy is 
complicated by the fact that it has a narrow therapeutic index and its enantiomers vary 
in pharmacokinetic and pharmacodynamic properties. Flavonoids are known to affect 
the bioavailability of drugs through cytochrome P450 modulation (2, 3, 4, 5, 6). 
Rutin, a flavonoid glycoside, and its aglycone quercetin are abundant in nature, 
especially in fruits and vegetables. Rutin is also widely found as a constituent of 
multivitamin preparations and herbal remedies. The present study was designed to 
investigate the potential drug interactions between rutin and warfarin in rats.  
 
In the single dose study, rats pretreated for four days with oral rutin (1 g in 1% CM-
cellulose/kg) or an equal volume (5 ml/kg) of 1% CM-cellulose (as the control), were 
given a single dose of racemic warfarin (1.5 mg/kg) orally. With the rutin regimen 
continued, blood samples were collected at different intervals over 96 h. In the 
multiple dose study, rats pretreated for five days with oral warfarin (0.15 mg/kg/day) 
to attain steady state, were given rutin (1 g in 1% CM-cellulose/kg) or an equal 
volume (5 ml/kg) of 1% CM-cellulose (as the control) orally along with the daily 
 ix
warfarin for another six days. Blood samples were collected at different intervals over 
168 h. The S- and R- enantiomers of warfarin in serum were separated and analyzed 
by high performance liquid chromatography. Plasma prothrombin time was measured.  
 
With the single dose of warfarin, hypoprothrombinaemia, as measured by reduced 
percentage of normal prothrombin complex activity, was observed in both rutin 
treated and control rats, but the recovery was found to be much faster in rutin 
treatment group compared to control animals. Of both S- and R- warfarin, the 
maximum serum concentration values, were increased, while the elimination half-life 
and apparent volume of distribution values, were significantly reduced with rutin 
treatment. There was an apparent increase in the rate of absorption and decrease in the 
time to reach peak serum concentration of both the enantiomers, though not 
statistically significant. With multiple doses of warfarin, rutin treatment resulted in 
higher percentage of normal prothrombin complex activity compared to control. Both 
rutin treated and control animals showed steady state serum levels of S- and R- 
warfarin with lower values of S- warfarin in the former group. Rutin treatment 
showed a trend to increase the steady state clearance, reduce the volume of 
distribution and elimination half-life, of S- warfarin.   
 
These results indicate a potential interaction between rutin and warfarin. As rutin and 
quercetin are present in numerous diets of plant origin, precaution must be taken 
before starting warfarin therapy in subjects who are on a diet rich in these 
bioflavonoids. 
 x
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 1
CHAPTER 1  INTRODUCTION 
 
Warfarin, a coumarin oral anticoagulant, is frequently used for the treatment and 
prevention of thromboembolic diseases. Racemate warfarin (mixture of R- and S- 
enantiomers) is normally used in clinical practice. S-warfarin is approximately five 
times more active than the R- isomer (7, 8) and is responsible for essentially all of the 
anticoagulant effects of the drug. It is also found to be more prone to drug 
interactions. Warfarin is highly bound to plasma protein (97.4-99%), especially 
albumin (8, 9). Given orally, warfarin is completely absorbed (10) and is metabolized 
by hepatic CYPs (11). S-Warfarin is metabolized by CYP2C9 to S-7-hydroxywarfarin 
in humans (11, 12), whereas R-warfarin is mainly oxidized to R-6-hydroxywarfarin, 
primarily by CYP1A2 and CYP3A4 (11, 12). Warfarin is a low extraction ratio drug 
(10). 
 
Flavonoids, an important family of antioxidants, are ubiquitous in edible plants, fruits, 
foods and medicinal botanicals (13, 14, 15). Flavonoids are known to affect the 
bioavailability of drugs through cytochrome P-450 (CYP) (15) and/or P-glycoprotein 
modulation (2, 3, 4, 5, 16). In general they occur in food as glycosides (4, 14). Rutin 
is a flavonoid glycoside abundant in the plant kingdom (14). Rutin derivatives (e.g. 
oxerutin and troxerutin) are used to treat various cardiovascular conditions (17, 18, 
19). Reports have shown its usefulness in treating abnormal fragility of the capillaries 
and as a vasoprotectant (20, 21, 22). Rutin is also reported to relieve venous 
insufficiency of the lower limbs and capillary impairment (18, 19). Rutin and its 
derivatives have been combined with oral anticoagulant such as warfarin in 
cardiovascular patients (23). Therefore, it could directly or indirectly influence some 
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of the metabolic pathways and thus affect the pharmacological actions of the co-
administered drug.  
 
Quercetin, the aglycone of rutin (24), meets the structural requirements for a strong 
antioxidant (24). Both quercetin and rutin form an integral part of various nutritional 
supplements and herbal preparations (25). Estimated average intake of quercetin in 
the USA is 20-22 mg per day (26). Consumption of rutin or quercetin diet resulted in 
the same conjugated metabolites in rat (14), pig (27) and human plasma (25, 28). 
Quercetin binds strongly to human serum albumin (HSA) (up to 99.1-99.4 ± 0.5 %) in 
vitro (24). When administered for a long time, quercetin accumulates in the blood and 
this could be attributed to its long elimination half-life (29). Quercetin has been 
shown to inhibit CYP3A4 enzymes in human microsomes in vitro (30), the enzyme 
responsible for the metabolism of R- enantiomer of warfarin. It also modulates P-
glycoprotein, a plasma membrane transporter (13). 
 
The present study was carried out to explore the pharmacokinetic and 
pharmacodynamic interactions of warfarin with rutin in rats, since warfarin is a 
commonly used oral anticoagulant (31) with wide variation in dose-response (32) and 
narrow therapeutic index and rutin is present in most of the foods, vegetables and 
dietary supplements. A retrospective clinical study has shown that patients with 
severe nonreconstructable chronic critical leg ischemia benefited from initial therapy 
with intravenous rutin combined with long-term oral warfarin treatment (23). To our 
knowledge, there have been no studies on the interactions between warfarin and rutin 
in rats. Thus, it was imperative to study the potential interactions between the two 
compounds.  
 3
1.1. LITERATURE REVIEW 
 
Warfarin is one of the most frequently used anticoagulants for the treatment and 
prevention of thromboembolic diseases. It has the advantage over heparin as it can be 
administered orally in long-term therapy. With low costs, it turns out to be 
economical to patients if taken for years. Some of the indications for warfarin therapy 
are listed out in Table 1.1.  
 
1.1.1. HISTORICAL PERSPECTIVE OF WARFARIN 
 
Oral anticoagulants were discovered accidentally in the 1920s when livestock in 
North Dakota fed decomposed sweet clover developed bleeding disorder (33, 34). The 
animals were progressively unable to form clots and bled to death after 30 days of 
ingestion. The disorder was reversible when the clover was removed from the feed or 
when the animals were transfused with fresh blood from unaffected animals. Vitamin 
K administration also reversed the condition. In 1934, bishydroxycoumarin 
(dicoumarol) was isolated and identified as the cause of the disorder. Warfarin, a 
coumarin derivative, was synthesized in 1944 and used as a highly effective rat poison 
initially. In 1951, an army inductee survived a suicide attempt after ingesting 567mg 
of warfarin (34). The hemorrhage was reversed by administering vitamin K and blood 
transfusion. This led to the widespread use of warfarin in clinics as an effective 
anticoagulant with vitamin K as an antidote if bleeding complications arose. 
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Table 1.1  Indications for warfarin therapy  
 
Treatment Target INR/ 
treatment 
duration 
















2-3 / 3 months 61 
Arterial 
Thromboses 
>3 / long-term 37 
Stents, filter devices,  
indwelling catheters 






2-3 37 Atrial fibrillation 2-3 / long-term 129 






2-3 / long-term 130 
Certain renal 
diseases 
 - 37 
Small cell 
lung cancer 
 - 37 
Post-surgery or 
immobilization 















and Factor V Leiden 
mutation 






Warfarin [3-(α-acetonylbenzyl)-4-hydroxy coumarin] is a single-ring coumarin 
derivative (8) (Fig. 1.1). It is weakly acidic (pKa 5.1) (35), insoluble in water and 
shows natural fluorescence with excitation at 290-342 nm and emission at 385 nm 
(36). The 4-hydroxycoumarin residue of warfarin with a nonpolar carbon substituent 
at the 3-position (asymmetrical carbon), is required for the pharmacodynamic 
properties (37). The 4-hydroxycoumarin ring binds to the reductase receptor. The side 
chain affects the disposition and metabolism of warfarin. Clinically warfarin is 
available as a racemic mixture of (R)- and (S)- enantiomers. 
 
1.1.3. PHARMACODYNAMICS 
1.1.3.1. Mechanism of action 
 
Vitamin K is an important cofactor for the enzymatic pathway of blood coagulation. It 
is essential for the γ-carboxylation of glutamate residues on inactive forms of clotting 
factors to γ-carboxyglutamic acid (8, 34, 38, 39, 40, 41, 42, 43). γ-carboxylation 
permits these coagulation proteins to undergo a conformational change in the 
presence of calcium ions (43, 44). In the absence of γ-carboxylation clotting factors 
are unable to bind to calcium ions and phospholipid surfaces through calcium ion 
bridges (8, 34) and have reduced activity. 
 
Warfarin acts as an anticoagulant by reducing the synthesis of the vitamin K-
dependent clotting factors like factor II, VII, IX and X and thus decreases the risk of 




















Figure 1.1 Warfarin chemical structure 
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inhibition of vitamin K reductase enzyme (Fig. 1.2), which is responsible for 
converting inactive vitamin K epoxide to active vitamin K (38, 39, 47). Thus warfarin 
blocks the regeneration of the active form of vitamin K and does so in a dose-
dependent manner. The time to deplete vitamin K to a threshold level so as to affect 
the synthesis of clotting factors is responsible for the delay in onset of action after the 
warfarin dose (8). Vitamin K stores in liver are eventually depleted. The anticoagulant 
response to warfarin is unpredictable and requires a careful monitoring for potential 
interactions. Age, diet, illness, patient compliance, genetic factors, physical activity, 
concurrent drug therapy and other unknown factors can affect the response to 




Warfarin is a drug of choice for the pharmacokinetic modeling. It has a reliable onset 
and duration of action and good bioavailability. (S)-warfarin is approximately five 
times more potent (7, 8) and is metabolized more rapidly than the (R)- isomer in man 
(8, 48). The concentration of each isomer in plasma therefore varies within and 
among patients. (S)- isomer is responsible for essentially all of the anticoagulant 
response of the drug and is found to be more prone to drug interactions. 
 
1.1.4.1. Absorption   
 
Warfarin is absorbed rapidly and almost completely when administered orally (8). 
The bioavailability of racemic warfarin solutions is almost complete also when 




Figure 1.2  Mechanism of warfarin anticoagulation 
Warfarin acts as an anticoagulant by reducing the synthesis of the vitamin K-
dependent clotting factors. Its anticoagulant effects are achieved by interfering with 
cyclic interconversion of Vitamin K via inhibition of vitamin K reductase enzyme, 
which is responsible for converting inactive vitamin K epoxide to active vitamin K. 































within 1 hour of its oral absorption (37). Peak blood concentration is reached within 
90 minutes (range between 2 to 8 hours) (37). The rate of absorption is delayed by the 
presence of food but the bioavailability is not affected. Table 1.2 shows various 
pharmacokinetic parameters, estimated in rats after oral ingestion of single and 
multiple doses of warfarin (49).  
 
1.1.4.2. Distribution  
 
The volume of distribution of racemic warfarin in man is found to be 0.09-0.17 L/kg 
(8). Warfarin is highly bound (97.4-99.9 %) to plasma proteins, mainly albumin. The 
relative serum protein binding of warfarin is independent of concentration over a 
broad range (50). Bound warfarin lacks its activity and is protected from 
biotransformation and excretion (8). The protein binding affinity differs between the 
two enantiomers of warfarin. The S- isomer has a greater affinity to protein binding in 
man compared to the R- isomer. Some of the drug interactions of warfarin by protein 
binding displacement may involve only one of the two enantiomers. Thus, highly 
protein bound acidic drugs can displace warfarin stereospecifically from the binding 
sites (8). Such interactions may be clinically significant, but may go undetected if 
only the racemate warfarin concentration is measured. However displacement from 
protein binding sites may cause only transient increase in the concentration of 
unbound warfarin as the total body clearance is increased with more unbound drug 
available at the elimination sites (8). 
 
Tissue binding of warfarin involves two classes of binding sites, one with high 
affinity and low capacity and the other with lower affinity and unlimited capacity (50) 
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Table 1.2  Pharmacokinetic parameters estimated in rats after oral ingestion of 
single and multiple doses of warfarin (49) 
 
                                   Warfarin (oral) Parameters 
Single dose (2 mg/kg) Multiple doses (0.2 mg/kg/day, 
for 6 days) 
Cmax (µg/ml) 7.8 ± 0.5 9.4 ± 1.4 
tmax (h) 2.6 ± 1.0 2.0 ± 0.0 
AUCa (mg.h/ml) 118 ± 22 133 ± 10 
t1/2 (h) 14.3 ± 5.8 16.3 ± 3.0 
Vd (ml/kg) 1483 ± 746 1419 ± 294 
CL (ml/h) 17.5 ± 3.3 15.0 ±1.0 
 
Values are mean ± S.D. (n = 6) 
Cmax, maximum plasma concentration; tmax, peak time; AUC, total area under plasma 
concentration-time curve; t1/2, elimination half life; Vd, apparent volume of 
distribution; CL, total plasma clearance; PT0, basal prothrombin time at time zero; 
PTmax, maximal PT achieved; Tmax,PT time to PTmax;    
a AUC0-∞ and AUC0-τ for single and multiple dose study, respectively. 
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Warfarin is extensively distributed to the liver and accumulates in microsomes to a 
large extent compared to other tissues (8) (Table 1.3), (50). Gathering evidence has 
shown the importance of hepatic uptake of warfarin as both plasma and tissue binding 
can affect the apparent volume of distribution and biological half-life of the drug (50). 
Hepatic uptake of warfarin is concentration dependent and is saturable with increasing 
concentration (50).  
 
Body fat takes up warfarin by partitioning rather than by albumin binding (50). A 
substance with apparent unlimited capacity, other than albumin, could be responsible 
for warfarin binding in fat (50). Warfarin also crosses the placenta and is teratogenic, 
but active warfarin is not found in milk (37). 
 
1.1.4.3. Metabolism and Excretion 
 
Warfarin metabolism in humans is catalyzed mainly by cytochrome P450 isoenzymes 
in the liver (11). Also, the acetonyl side chain ketone moiety is reduced by ketone 
reductases (51). Metabolites include 4’-hydroxywarfarin, 6-hydroxy warfarin, 7-
hydroxy warfarin, 8-hydroxy warfarin, 10-hydroxy warfarin, dehydrowarfarin and 
two pairs of diastereomeric warfarin alcohols (52). (S)-7-hydroxywarfarin is the 
predominant metabolite of (S)-warfarin in human and R-warfarin is mainly oxidized 
to (R)-6-hydroxy warfarin (12). The metabolites of warfarin do not appear to 
contribute to the activity of the drug. But metabolite estimation helps in understanding 
the source of variation and mechanism of interaction of drugs with warfarin. A better 
understanding of the warfarin drug interactions could be possible by either giving 
each enantiomer individually (a rare clinical practice) or using a stereo specific assay  
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Table 1.3  Apparent binding and tissue-serum partition constants for S-warfarin in 
rat tissues (50) 
 
Tissue Tmax, (µg/g) Kd, (µg/ml) R 
Liver 0.666 - 0.251 
Kidneys 0.161 - 0.195 
Muscle 0.0405 - 0.0441 
Fat 0.0174 8.46 X 10-4 2.85 
 
Tmax, theoretical maximum capacity of the low capacity binding sites; Kd, 
dissociation- constant of S-warfarin-low capacity binding sites; R, ratio of the S-
warfarin concentration in a tissue to that in serum. 
Tmax and R decreased in the order: liver > kidneys > muscle 
 13
to measure the plasma concentration of each isomer after the administration of the 
racemate drug (53). 
 
Cytochrome P450 monooxygenase or CYP is the most important group of liver 
enzymes catalyzing phase- I metabolic biotransformation reactions (54). It has a broad 
range of substrate specificity. These heme-containing mixed-function oxidases 
catalyze the oxidation of a majority of chemical substances in the liver. Substrates of 
the human CYP isoenzymes are identified by assessing their metabolism directly with 
human CYP isoforms or by inhibiting their metabolism with antibodies or selective 
inhibitors. Hepatic P450 system consists of a number of isoforms.  
 
CYP1 family is composed of at least two subfamilies, CYP1A and CYP1B. The well-
characterized CYP1A subfamily consists of two members, CYP1A1 and CYP1A2. 
CYP1A2 is mainly confined to the liver. In humans it appears to be mainly 
responsible for the mutagenic activation of several heterocyclic amines. CYP2C 
subfamily is the largest of mammalian liver enzymes and has been studied most 
extensively (55). In humans, CYP2C8, CYP2C9, CYP2C18 and CYP2C19 have been 
expressed in liver, CYP2C9 being the most abundant. Human CYP2C enzymes 
metabolize a number of drugs, such as mephenytoin, warfarin, tolbutamide and 
phenytoin. (S)-warfarin 7-hydroxylation is almost exclusively catalyzed by CYP2C9 
in humans (11). (R)- isomer 7-hydroxylation is carried out by several CYP enzymes, 
but primarily by CYP-1A2 and 3A4 (11).  
 
CYP3A enzymes appear to be of great importance in man, major form being 
CYP3A4. It is the most versatile of the P450 superfamily, being involved in the 
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metabolism and activation of a number of structurally unrelated compounds (56). It is 
responsible for numerous drug interactions and is inducible by a number of 
structurally unrelated drugs and xenobiotics. Drugs metabolized by CYP3A4 include 
protease inhibitors, calcium channel blockers, benzodiazepines, estrogens, 
cyclosporins, cortisone etc (57). Significant amount of CYP3A4 is present in the gut 
wall epithelium and thus metabolizes many drugs before absorption (56).  
 
Carbonyl reductases are a group of enzymes present widely in cytosolic and 
microsomal fractions of various tissues, but mainly in the liver. They reduce carbonyl 
groups of a number of drugs and endogenous substances and are NADPH- dependent. 
Ketone reduction results in the formation of alcohols. Microsomal ketone reductases 
differ from cytosolic ketone reductases in stereoselectivity. In in-vitro reduction of 
warfarin in the rat and in man, marked substrate selectivity is shown for (R)- 
enantiomer which is reduced mainly to (RS)- alcohol. The same stereoselectivity for 
product and substrate is shown in the in-vivo ketone reduction in man. In the rat, in-
vivo reduction is selective for (S)- warfarin, reducing it to (SS)- alcohol (51).     
 
Warfarin is excreted mainly as its metabolites by the kidneys in urine and stool. 15-20 
% of the oral warfarin is excreted in the urine as the alcohols (11). The average 
warfarin plasma clearance rate is 0.045 ml.min-1.kg-1. The elimination half-life is 
between 25-60 hours (mean 40 hours) (37). Some of the pharmacokinetic parameters 
for warfarin elimination in different species are compiled in Table 1.4. The table can 
serve as a basis for comparing the pharmacokinetics of warfarin in different species. 
For example, the data shows that, unlike in man, S-warfarin is eliminated more slowly 
than R-warfarin in rats (58). Limitations of the data include, fewer number of animals  
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Table 1.4  Comparison of reported pharmacokinetic parameters of warfarin 
elimination in different animal species 
 
Mean elimination half-life (t1/2) (h) ±S.D 
Subject S-Warfarin R-Warfarin Racemic 
warfarin* 
Reference 
13.85±4.33(10) 7.26±1.82(10) 11.56±3.73(10) 132 
22.4 a (11) - - 133 
23.6±4.6 (10) 17.5±2.2(10) - 108 
- - 7.07 a (13) 134 
- - 10.4 a (2) 59 
Rat 
19.5±3.4(10) 11.9±3.9(10) - 104 
33±12.65(10) 58±15.81(10) 42±6.32(10) 7 
30.5±13.96(6) 41.2±4.16(6) 36.2±19.2(6) 135 
33±14.6(6) 43.4±8.4(6) - 105 
37±35(12) 53±14(12) - 136 
27.5±7.38(6) 36.8±14.23(6) - 137 
36±13(6) 46±7(6) - 138 
- - 36.3±3.5(12) 139 
- - 43±10(30) 59 
Man 
- - 34 a (10) 134 
- - 22 a (2) 59 Dog 
- - 18.4±4.6(4) 140 
Monkey - - 14.4 a (4) 59 
4.27±0.56(4) 6.39±0.36(4) 5.6±1.84(8) 141 Rabbit 
- - 10.89±1.24(4) 142 
Clearance (CL) (ml/min/kg body wt) ±S.D 
Subject S-Warfarin R-Warfarin Racemate Reference 
0.08 a (11) - - 133 Rat 







0.108±0.036(6) 0.077±0.017(6) - 138 
- - 0.0367 a (10) 134 
Man 
3.52±1.13 (6) 2.61±0.37 (6) 2.96±0.64(6) 135 
2.82±0.54(4) 0.73±0.08(4) 1.33±0.23(8) 141 Rabbit 
- - 3.15 b ±0.4(4) 142 
Plasma unbound fraction (fu) ±S.D 




































- - 0.08 a (10) 134 




Number of animals or subjects in parenthesis; * Racemic warfarin, a mixture of (R)- 
and (S)- enantiomers, was estimated by UV spectrophotometric/fluorometric method; 
a S.D values not available; b CL is expressed as ml/min  
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studied in some cases, possible differences of strain and sex and variation in 
experimental conditions (59). 
 
Physiologic pharmacokinetic models are useful in understanding the time course of 
drug concentrations in plasma as well as in main organs and tissues in animals (60). 
Fig. 1.3 represents a physiologically based pharmacokinetic model for (S)-warfarin 
disposition in rats (60). This model requires estimation of actual drug concentration in 
various organs and tissues. Each of the assayed tissue was included as a separate 
compartment and the unanalyzed pooled into “rest of body” compartment. The model 
is based on the assumption that blood flow is solely responsible for the drug transport 
between compartments and the drug reaches equilibrium between tissue and blood 
instantaneously. Also it was assumed specifically for S-warfarin that elimination was 
solely through hepatic metabolism. 
 
Physiologic pharmacokinetic models cannot be used in humans for obvious reasons, 
as data required are available only from animal studies. But useful alternatives of 
target-mediated pharmacokinetic models are available. Such models also allow 
characterization of data from the literature for racemic warfarin pharmacokinetics in 
man (60).  
 
1.1.5. MEASUREMENT OF ANTICOAGULATION 
 
Warfarin has a low therapeutic index. Careful monitoring of the patient is required to 
maintain the therapeutic window. The anticoagulant effect of warfarin is mainly 
monitored by the prothrombin time (PT) assay (34). PT reflects changes in three of 
















Figure 1.3  Physiologically based pharmacokinetic model for (S)-warfarin 
disposition in rats (60) 
Blood flow rates in different tissues is represented by “Q”; CL’, Intrinsic clearance. 
 
Each of the assayed tissue was included as a separate compartment and the rest pooled 
as a remainder. The model is based on the assumption that blood flow is solely 
responsible for the drug transport between compartments and the drug reaches 
equilibrium between tissue and blood instantaneously. Also it was assumed 















It is most sensitive to the level of clotting factor VII during the first few days of 
therapy (61). PT is based on the time to form a clot after the addition of 
thromboplastin and calcium to the citrated plasma. The PT result may vary depending 
on the type of thromboplastin used in the reagent. The international normalized ratio 
(INR) may be used to standardize the results from different laboratories. A correction 
factor, international sensitivity index (ISI), assigned to each reagent is used to 
calculate INR from PT values. Ratio of patient PT to mean PT from normal people 
raised to the ISI power gives INR. 
 
1.1.6. CHEMICAL ANALYSIS 
 
Due to the differences in pharmacokinetic and pharmacological actions of 
enantiomers, chiral separation and assay in biological sample becomes an important 
consideration. High-performance liquid chromatography (HPLC) is one of the most 
commonly used analytical techniques for this purpose. Various non-stereospecific 
HPLC assays have been developed for warfarin in biological samples such as a 
reversed-phase HPLC with post-column alkalinization to increase fluorescence 
detection (62). However, chiral or achiral methods were used to selectively separate 
the enantiomers (63). Chiral separation techniques by HPLC can be carried out either 
by using chiral HPLC columns such as α1-acid glycoprotein or β-cyclodextrin 
columns or by incorporating chiral reagents into HPLC mobile phase on achiral 
columns (64). Achiral procedures involve precolumn derivatization of enantiomers to 
diastereomeric esters using chiral derivatising agents and separation by normal-phase 
HPLC (65) or reversed-phase HPLC (66).   
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Chiral separation technique for warfarin enantiomers by normal phase HPLC was 
reported by Banfield, C. and Rowland M. 1984 (65) (Fig. 1.4). The assay method is 
able to successfully separate the enantiomers and detect fluorimetrically. It was found 
to be highly sensitive and specific. 
 
1.1.7. WARFARIN DRUG INTERACTIONS 
 
Drug interactions involving oral anticoagulants are broadly classified as 
Pharmacokinetic, Pharmacodynamic and Allergic or Idiopathic. Pharmacokinetic 
interactions involve changes in pharmacokinetic parameters such as clearance, half-
life or volume of distribution. They are accompanied by changes in the amount of 
anticoagulants and are caused by alterations in protein binding, metabolism, 
absorption and/or excretion. Drugs may affect the pharmacodynamics of warfarin by 
increasing the metabolic clearance or inhibiting the synthesis of vitamin K-dependent 
coagulation factors, and/or by interfering with various pathways of hemostasis (61).  
Pharmacodynamic interactions can be synergistic or antagonistic and result in 
expected or nonpredictable activity. Generally no change in the circulating amounts of 
the anticoagulant is observed in these interactions. Idiopathic interactions are those 
with no known mechanism of interaction. One example is the interaction between 
ascorbic acid and oral anticoagulants (33). 
 
Interactions affecting the pharmacokinetics of drugs are difficult to anticipate as they 
might result from various factors involving absorption, distribution, metabolism and 
excretion. Metabolism appears to be the major source of interaction in humans. 












Figure 1.4  Schematic instrumental setup for chiral separation of warfarin 















reactions catalyzed by specific CYP isozymes. This is emerging to be important 
mechanism for understanding the nature of drug interactions (55). A drug which 
inhibits CYP2C9 to a considerable extent can have a major impact on the warfarin 
anticoagulant response because the clearance of (S) - warfarin is reduced. Thus 
Fluvastatin, which is a potent inhibitor of the CYP2C9 isoenzyme, affects clinical 
anticoagulation more than the other statins (67). 
 
Routinely warfarin may be a part of multiple drug therapy regimens and drug 
interactions constitute a major problem of chronic polypharmacy. Pharmacokinetic 
interactions of warfarin are generally accompanied by changes in the warfarin 
circulating in blood. These interactions would lead to either loss of anticoagulation or 
increased risk of bleeding. Some of the interacting drugs as listed out in Table 1.5 
include amiodarone, propafenone, benzbromarone, barbiturates, fluconazole, 
cimetidine, metronidazole, trimethoprim-sulphamethoxazole combination, 
clonazepam, NSAIDs like phenylbutazone, bucolome. The list shows that most of the 
major categories of therapeutic agents can interact with warfarin. 
 
In spite of negative pre-marketing drug interaction studies, post-marketing drug 
interactions have been reported for many drugs. Stereoselective inhibition of P450-
2C9 leading to enhanced metabolism of (S)-warfarin has been demonstrated for 
miconazole, metronidazole, sulfinpyrazone, phenylbutazone, enoxacin, amiodarone, 
tricynafren, cimetidine, and omeprazole. Metabolically based drug interaction with 
fluconazole has been reported, with fluconazole inhibiting CYP-2C9 and 3A4. 
Bucolome is known to be a clinically potent inhibitor of CYP2C9 (68). Uricosuric 
drug benzbromarone inhibits CYP2C9-metabolism of (S)-warfarin. Fluvoxamine, 
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a Increase warfarin effect; b Decrease effect; c either increase or decrease effect 
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inhibitor of CYP-1A2, 3A4 and 2C9, is the most likely of SSRIs to interact with 
warfarin (69). Recently a possible interaction between warfarin and menthol cough 
drops has been reported (70). Though the mechanism of decrease in anticoagulation is 
not known, menthol is known to affect the CYP 450 metabolism. 
 
1.1.7.1. Warfarin interactions with complementary and alternative medicines 
(CAM) 
 
Recent reports show that the use of CAM is on the rise among patient populations 
throughout the world. Most of them use it for the treatment of chronic, incurable 
diseases including cancer and HIV/AIDS (71). With the surge in chronic diseases and 
the potential side effects of modern drugs, patients often explore various CAM (72). 
General public is of the opinion that “naturalness” is a guarantee for “harmlessness”. 
About 50% of Americans use dietary supplements to treat various ailments and up to 
20% use these products regularly (69). Along with the prescribed polypharmacy, 
patients take numerous over-the-counter medications, vitamins, herbs and foods. All 
these have the potential to interact. It is known that substances that inhibit cytochrome 
P450 isoforms have higher potential for drug interactions (73). But experimental data 
on herb-drug interactions are limited and scarce (74). Potential interactions of 
alternative medicine products with prescription medicines are all the more important 
in case of drugs with narrow therapeutic index (1). Therapeutic effects of such drugs 
add up due to interaction and the cumulative effect can be unpredictable. It may 
require a careful monitoring of the therapy.   
 
Potential and documented interactions have also been reported between herbal 
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supplements and warfarin (Table 1.6) (1, 74, 75, 76). Numerous food and drug 
interactions of warfarin have been reported when compared to any other medication 
(1). Interactions with warfarin could be through various pathways. Patients who took 
warfarin along with traditional Chinese medicinal (TCM) herbs as food supplements 
have had warfarin adverse effects enhanced (77). Addition of prescription drugs to 
“herbal” products is ubiquitous with Chinese patent medicines (74). Quilinggao 
(“essence of tortoise shell”) is one such popular Chinese herbal product that is 
reported to have caused bleeding when administered with warfarin (78). It contains 
various ingredients that interact with warfarin. Therefore estimating and managing 
warfarin interactions with herbal products are very important. Most of the available 
information on potential drug interactions between warfarin and herbal products is 
based on in vitro data, animal studies, or individual case reports. Definite mechanisms 
for such interactions are yet to be established (1). 
 
New drug products are routinely examined in vitro and in vivo for the potential to 
cause drug interactions via inhibition of drug-metabolizing enzymes (73). But herbal 
preparations are not subject to such tests. Thus the potential exists that herbal 
preparation could cause drug interactions when administered with other medications. 
Herbal products that have been associated with published case reports of possible 
interactions with warfarin include danshen, devil’s claw (harpagophytum 
procumbens), dong quai, green tea, ginkgo biloba, ginseng and papain. Dietary 
supplements like coenzyme Q10 and vitamin C, E and K have also been reported to 
adversely affect warfarin therapy (1). Dong quai, fenugreek, horse chestnut, red clove, 
sweet clover, sweet woodruff and chamomile contain coumarin like substances and 
have the potential to interact with warfarin (1). Furanocoumarins from ethyl acetate    
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Table 1.6  Warfarin interactions with herbs and herbal products (1, 69, 75, 76, 119) 
(Partial list) 
 Interaction  Interaction 
Ginseng 

























































extract of grapefruit juice have decreased the activities of CYP-3A4, 1A2, 2C9, and 
2D6 (79) and reported to inhibit 7-hydroxylation of coumarins in healthy volunteers 
(80). Excessive doses of Kangen-karyu, an anti-thrombotic TCM, prolonged the 
bleeding caused by warfarin by suppressing its metabolism (72). Thus benign use of 





Flavonoids are a diverse class of polyphenolic compounds found in plants (81). 
Flavonoids are divided into following groups: flavans, flavanones, isoflavanones, 
flavones, isoflavones, anthocyanidines, chalcones and flavonolignans (82). All 
flavonoids have the same basic structure, a three-ringed molecule with hydroxyl 
groups attached (C6-C3-C6) (Fig. 1.5). They occur in foods as a glycoside and have 
numerous biological activities in animals (81). The approximate daily intake of 
flavonoids from food in different countries is 3-70 mg with higher values in regions 
where intake of tea and vegetables is high. Their actions are related either to the 
chemical structure or to the enzyme activity.  
 
Flavonoids are known to affect the bioavailability of drugs by interacting with P-
glycoprotein multiple drug transporters (16) or through cytochrome P450 modulation 
(2). In general, it is found that flavonoids containing hydroxyl group inhibit 
cytochrome P450 enzymes and flavonoids devoid of hydroxyl groups often stimulate 
the enzyme activities (82, 83). Flavonoids can stimulate or inhibit cytochrome P450 
depending on the structure, amount and experimental conditions (4). 
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1.1.8.2. Rutin and Quercetin  
 
Rutin and its metabolite quercetin are the flavonoids widely distributed in the plant 
kingdom. Rutin was introduced as capillary stabilizer in 1949 (84). It can be prepared 
from Buckwheat or red beans (85). Rutin is soluble in hot ethyl alcohol (5%), 
precipitating slowly on cooling (20). It is one of the main flavonoids present in 
Hypericum species. Table 1.7 summarizes some of the available information on rutin. 
The physiological functions of rutin include inhibition of capillary permeability and 
enhancement of capillary resistance, anti-inflammatory, antihydropic, aldose 
reductase inhibition and improvement in glaucoma by diabetes. Rutin is found to 
relax smooth muscles and lower hepatic and blood cholesterol in rats (86). Rutin 
derivatives (e.g. oxerutin and troxerutin) are used to treat various cardiovascular 
conditions (17, 18, 19). It is also reported to relieve venous insufficiency of the lower 
limbs and capillary impairment (18, 19). Rutin is known to be a strong scavenger of 
superoxide and hydroxyl radicals and as an antioxidant. It is used against lipid 
peroxidation, used as a coloring agent, nutrient, food additive (enzymatically 
decomposed rutin) (85) and in cosmetics. 
 
Quercetin is found in citrus fruits, apples, onions, parsley, Gingko biloba, St John’s 
wort, Echinacea purpurea, tea, red wine and other fruits and vegetables. It is the most 
abundant of the flavonoid molecules. It acts as an antioxidant. Quercetin is the 
aglycone of different flavonoids, including rutin (quercetin 3-O-glucose-rhamnose), 
quercetrin, isoquercetrin (quercetin 3-O-glucose). (Aglycone is the non-sugar 
compound remaining after replacement of the glycosyl group from a glycoside). It has 
higher activity when compared to these flavonoids. Thus both rutin and quercetin  
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Table 1.7  Drug information: Rutin (145) 
 
Rutin a flavonol glycoside of quercetin and rutinose 
Description Pale yellow substance, slightly soluble in water 







Other names Rutoside; quercetin-3-rutinoside; sophorin; 3, 3', 4', 5, 7- penta-        
hydroxyflavone-3-rutinoside; 3-rhamnosyl-glucosyl quercetin; 
3-[[6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-gluco 
pyranosyl] oxy]-2-(3, 4-dihydroxyphenyl)-5,7-dihydroxy-4H- 
1-benzopyran-4-one 
Actions Antioxidant, anti-inflammatory, anticarcinogenic, antithrombotic, 
cytoprotective and vasoprotective 
Indications Venous edema, varicose veins; to strengthen capillaries; as anti- 
inflammatory; against some toxins; anticancer; prevents oxidation 
of vitamin C 
Adverse 
reactions 
generally well tolerated; nausea, headache, mild tingling of the 
extremities 
Interactions Quinolone antibiotics, vitamin C, processed meat products 
Dose 500 mg once/twice daily 
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present in Ginkgo biloba extract cause vasorelaxation, but quercetin has a stronger 
relaxation than rutin (87). Bioavailability of quercetin is affected by attaching or 
detaching a glucose molecule, but not by the position (88). It has effective anti-cancer, 
anti-ulcer, anti-allergic, anti-inflammatory, antiviral activities and gives 
cardiovascular protection and prevents diabetic cataracts. It is often used for allergic 
conditions such as asthma, hay fever, eczema, hives and also to treat gout, pancreatitis 
and prostatitis. Rutin and quercetin have low solubility in biological fluids (17, 89).  
  
Quercetin strongly inhibits the activity of carbonyl reductases, the enzymes 
responsible for the biotransformation of various drugs and endogenous compounds, in 
vitro (90). Thus it can possibly affect the metabolism of drugs that are metabolized by 
carbonyl reduction such as quinines and warfarin. Furthermore, quercetin inhibits 
CYP3A4 enzymes in both human and rodent microsomes in vitro. CYP1A2 is most 
susceptible to quercetin inhibition (91). Effect of quercetin on CYP2C9 and CYP3A4 
were recently studied in human liver microsomes (6). Ginseng quercetin inhibited 
both CYP2C9 and CYP3A4 significantly (6). Though in vivo data was not available, 
the results indicate that quercetin is capable of inhibiting the metabolic reactions 
mediated by CYP2C9 and CYP3A4 and thus have potential interactions with drugs 
metabolized by these enzymes. Quercetin is also reported to increase the expression 
of CYP1A1 (82).    
 
Severe anticoagulation was reported in a patient who consumed a non-steroidal anti-
inflammatory herbal drug with rutin as one of its constituents (92). The interaction 
could have been possibly due to contamination with coumadin, but the potential 
interaction with rutin has not been studied yet. Troxerutin, a rutin derivative, is known 
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to heal capillary endothelial defects and shown to be beneficial in combination with 
coumarin for treating chronic venous insufficiency (93). It was observed to protect 
liver from lipid peroxidation caused by coumarin (93). Rutin was reported not to have 
interacted with in vitro liver microsomal cytochrome P-450 dependent 
monooxygenases in a study. But many of the results of this study could not be 
extrapolated to in vivo studies (89).  However, rutin could directly or indirectly 
modify the metabolic pathways of other active constituents, thus affecting the 
pharmacological actions of the interacting drug.   
 
The absorption, metabolism, transportation and delivery of flavonoids to specific 
tissues may influence the effect of flavonoid-rich diet on health (94). There have been 
many contradictory reports on the mechanisms of absorption of flavonoids from the 
gastro-intestinal tract (25). Rutin is absorbed more slowly than quercetin in rats and 
humans (95). The former is likely to be hydrolyzed by the digestive microflora and 
converted to quercetin prior to being absorbed (14, 25, 95) though absorption of some 
of the intact flavonoid glycosides has been reported recently (96). Glucuronides 
and/or sulfates of quercetin and unconjugated quercetin aglycone, with no rutin, were 
detected when quercetin (8-50 mg dose) and rutin (16-100 mg dose) were 
administered orally to healthy volunteers (25) (Table 1.8). With a single oral dose of 
1 g/kg body weight, quercetin and rutin were detected in the body as aglycone or 
conjugates of quercetin and isorhamnetin up to three days post dose (97). 
 
Pharmacokinetic variables of absorption and elimination of quercetin in human 
plasma after ingestion of various flavonoid foods are summarized in Table 1.9 (88, 
98, 99). Table 1.10 shows the total area under plasma concentration-time curve and  
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Table 1.8  Pharmacokinetic parameters of oral quercetin and rutin in human plasma 
 
Quercetin Rutin Pharmacokinetic 
parameters 8 mga 20 mga 50 mga 16 mga 40 mga 160 mga 200 mgb 
Cmax 41.4 66.1 86.1 23.5 47.6 89.9 320 
tmax 1.9±1.2 2.7±1.9 4.9±2.1 6.5±1.8 7.4±2.2 7.5±2.2 6.98±2.9
AUC0-24 527 882 1138 381 636 1017 2500 
t1/2 17.1±3.7 17.7±2.6 15.1±3.0 - - - 11.8±3.1
Protein binding c 
Plasma 
HSA (40mg/ml) 
99.1 ± 0.5 






134 ± 6 
50 ± 8 
10.7 ± 6.6 
- 
 
a Values are mean (± S.D for tmax and t1/2); (n = 16) (25)  
b Values are mean (± S.D for tmax and t1/2); (n = 12) (28) 
c Values are mean (± S.D) fractions (%) of quercetin (1.5-15 µM) bound to plasma; 
(n=5) (117)    
d Values are mean (± S.D) (n=4) (94) 
Cmax, maximum plasma concentration, (µg/l); tmax, peak time, (h); AUC0-24, total area 
under plasma concentration-time curve from time zero to 24 h, (µg h/l); t1/2, 
elimination half life, (h); HSA, human serum albumin; K1, Binding constant (103 M-1); 
BSA, bovine serum albumin. 
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Table 1.9  Pharmacokinetic variables of absorption and elimination of quercetin 
from various foods/sources in human plasma (88, 98, 99) 
 





Onions Apples Rutinoside Quercetina,b
Cmax 1526 1345 224±44 92±19 90±93 - 
tmax 0.617 0.45 0.7±1.08 2.5±0.72 9.3±1.8 - 
AUC0-36 - - 2330±849 1061±375 983±978 - 
AUC0-72 5775 5276 - - - - 
t1/2 18.5 17.7 28±92 23±32 - 2.4 
      Amount  
in urinec 9.75 8.61 3.2±1.6 1.45±0.7 1.17±1.34 - 
Vd - - - - - 0.34 
CL - - - - - 34.26 
 
Values are mean ± S.D (n = 9)  
a S.D values not available 
b Quercetin administered i.v. (100 mg) 
c Amount of quercetin excreted in 24 h urine (µmol)   
Cmax, maximum plasma concentration, (µg/l); tmax, peak time, (h); AUC0-36, total area 
under plasma concentration-time curve from time zero to 36 h, (µg h/l); AUC0-72, total 
area under plasma concentration-time curve from time zero to 72 h, (µg h/l); t1/2, 
elimination half life, (h); Vd, apparent volume of distribution (l/kg); CL, total plasma 
clearance (l/h). 
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Table 1.10  Total area under plasma concentration-time curve (AUC0-24) and mean 
(± S.E) 24 h urinary excretion of quercetin and methylated quercetin in rats 
administered quercetin and rutin (100) 
 
 
Supplement Metabolite AUC0-24 
(nmol/h) 
Urinary excretion 
(nmol/24 h urine) 
quercetin 4.13 32.4 ± 14.1 Quercetin 
methylated 
quercetin 1.91 50.7 ± 20.2 
quercetin 9.97 59.1 ± 10.3 Rutin 
methylated 
quercetin 9.75 173.4 ± 40.2 
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mean 24 h urinary excretion of quercetin in rats administered quercetin and rutin 
(100). Further quercetin has been reported to accumulate in the blood when 
administered for a long time and is attributed to its long elimination half-life (98).  
 
A recent report estimates that 15 million people in United States and 3.7 million in 
Australia may be at risk of drug-supplement interactions (75). Some of the available 
on-line resources for herbal product drug interaction are listed out in Table 1.11. 
Though confirmed drug-herb interactions are rare, adverse reactions remain under-
reported most of the time. So the total figures could be much higher. If this is the case 
in the United States and Australia, then Singapore and most of the Asian societies 
might be at a greater risk as many of the traditional alternative medicines using herbs 
originated from these Asian countries and are still being used widely. The main 
purpose of this project is to study the pharmacokinetic and pharmacodynamic 
interactions of warfarin with rutin in rats, with particular emphasis on enantiomeric 
composition following administration of the racemic drug. 
 
The present study was designed to carry out quantitative analysis of serum warfarin 
levels, with emphasis on individual enantiomers. The effect of rutin on the degree of 
anticoagulation was assessed by means of one-stage prothrombin time. Also rutin 
treatment study in the absence of warfarin was carried out to evaluate the effect of 
rutin alone on blood coagulation in rats. 
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Table 1.11  On-line resources for herbal product interaction with warfarin (69) 
 
The natural Pharmacist                                  www.tnp.com 
The Pharmacist’s Letter                                www.naturalpharmacist.com 
National Institutes of Health                         http://dietary-supplements.info.nih.gov 
Special Nutritionals                                      http://vm.cfsan.fda.gov 
Adverse event monitoring- 
MEDWATCH Reporting                             www.fda.gov/medwatch                          
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CHAPTER 2  OBJECTIVES 
 
In this study, the potential drug interaction between rutin, a flavonoid glycoside and 
warfarin, the most widely prescribed oral anticoagulant, was investigated in rats. 
Warfarin drug interactions are clinically relevant due to its narrow therapeutic 
window. Since rutin and quercetin are present in numerous diets of plant origin, 
potential for drug interactions before and after starting warfarin therapy in subjects on 
rich diet of these bioflavonoids was evaluated in rats.  
 
The study was designed to investigate the effects of both single (1.5 mg/kg) and 
multiple (0.15 mg/kg) oral doses of racemic warfarin in rats treated with and without 
rutin (1 g/kg). Quantitative analysis of serum warfarin levels, with emphasis on 
individual enantiomers, was carried out. The effect of rutin on the degree of 
anticoagulation was assessed by means of the one-stage prothrombin time.  
 
Also, another study was designed separately to study the effect of rutin alone on blood 
coagulation. 
 39




Warfarin is the oral anticoagulant of choice in most of the countries (66). However 
about 250 drugs and a whole lot of nutritional supplements and herbal preparations 
are known to potentially interact with warfarin (75). Possibility of unearthing 
potential interactions in the future is immense. Rutin is present in many of the often-
consumed foods, vegetables and medicinal botanicals. It is also widely used in 
complementary and alternative medicines. Thus potential drug interaction between 
rutin and warfarin needs to be evaluated.  
 
In this part of the study, rats were treated with rutin orally for four days before 
administering a single dose of warfarin to possibly mimic a clinical case of 
introducing warfarin in a patient who has been on rutin either from diet or herbal 




The experiment was designed to study the effect of rutin on pharmacokinetic and 
pharmacodynamic properties of warfarin administered as a single oral dose in rats. 
Concentrations of each of the warfarin enantiomers were quantitatively estimated in 
serum by HPLC assay and pharmacokinetic parameters calculated. Also the effect of 
rutin on prothrombin time was measured.  
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3.3. MATERIALS AND METHODS 
3.3.1. Chemicals and reagents 
 
Racemic warfarin, chlorowarfarin, and carbobenzyloxy-L-proline were obtained from 
Aldrich Chemical Company, Milwaukee, USA. 1, 3-dicyclohexylcarbodiimide was 
purchased from Sigma-Aldrich Chemie GmbH, Steinheim, Germany. Rutin hydrate 
from Sigma Chemical CO, St. Louis, MO, USA, and carboxy methyl cellulose (CM-
Cellulose), sodium salt and quercetin dihydrate from Sigma-Aldrich CO, St. Louis, 
MO, USA were used for the study. Trisodium citrate dihydrate GR and sodium 
chloride GR were purchased from E. Merck (Darmstadt, Germany). The solvents n-
hexane (GR, Merck KgaA, Darmstadt, Germany), butylamine (Merck-Schuchardt, 
Germany), methanol and acetonitrile (Mallinckrodt chrom AR®HPLC), ethyl acetate 
(HPLC) and diethyl ether (Analytical reagent AR) (both obtained from Lab Scan 
Analytical sciences, Bangkok) were used for the study. 10X PBS (Phosphate buffer 
saline containing 80 g/L NaCl, 2 g/L KCl, 14.4 g/L Na2HPO4, and 2.4 g/L KH2PO4; 
pH 7.4) was purchased from National University Medical Institutes (NUMI), 
Singapore.  
 
The sodium citrate solution was prepared as an anticoagulant according to the 
reported method (101) based on Owren’s theory of blood coagulation. (Sodium citrate 
solution – 231 ml of 34.2 mM Sodium citrate + 200 ml of Owren’s buffer + 569 ml of 
0.9% NaCl). Formulations of rutin were prepared just before use by weighing and 
suspending in 1% CM-cellulose. Neoplastine® CI Plus 5 kit (Cat. No. 00375) was 
obtained from Diagnostica Stago (France). The kit reagents consist of Reagent 1 
(freeze-dried thromboplastine prepared from fresh rabbit cerebral tissues) and 
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Reagent 2 (aqueous solvent containing calcium with sodium azide as a preservative, 
5-ml per vial). The ISI (International Sensitivity Index) values of Neoplastine, 
determined against a secondary standard of the rabbit brain thromboplastine, were 
1.21 and 1.22 for Lot Nos. 022571 and 013334, respectively. The reagent contains a 
specific heparin inhibitor. Any prolongation of the prothrombin time is related to a 
real deficiency of the prothrombin complex activity. 
 
Rat cubes, the standard diet for laboratory animals fortified with vitamins and 
minerals, were purchased from Glen Forest Stockfeeders, Australia. Milli-Q water 
from the Millipore® Continental Water Systems (Burlington, MA, USA) was used for 




The high performance liquid chromatography (HPLC) system for the assay of 
warfarin enantiomers consisted of a solvent delivery system (LC-10AT, Shimadzu), 
sample injector with standard sample loop (20 μl), a fluorescence detector (RF-
10AXL, Shimadzu), a communication bus module (CBM101, Shimadzu), a computer 
and a workstation (Class-CR10, Shimadzu). The chromatographic conditions for 
isocratic normal phase HPLC were as follows: A stainless steel column (250 × 4 mm) 
packed with silica (MAXSIL 10 silica, 10 micron, Phenomenex, USA) maintained at 
23°C column temperature, was used for the separation. Mobile phase was a mixture of 
ethyl acetate/n-hexane (22.5:77.5) at a flow rate of 0.8 ml/min. Bed reactor (stainless 
steel column 3 mm i.d., 25 cm) packed with glass beads (40 μm) was used for the post 
column aminolysis. Butylamine/methanol (1:1) was used as the post column reagent 
 42
at a flow rate of 0.4 ml/min. The effluent from the column was detected by excitation 
at 313 nm and emission at 400 nm using a fluorescence detector. 
 
For the prothrombin time (PT) test, fully automated coagulation analyzer (Sysmex 
automated blood coagulation analyzer, CA 530, Sysmex Corporation, Kobe, Japan) 
was used. Siliconized capillary tubes for orbital bleeding (1.3 mm ID, 50 mm length, 
Fisher Sc. US) siliconized with dimethyl dichlorosilane, 1.5 ml capacity micro 
centrifuge tube- with 250 μl sodium citrate in it and Heparinized microhematocrit 
capillary tubes (1.1-1.2 mm ID) were used for blood sampling. 
 
3.3.3. Animals and sampling method 
 
Adult male Sprague-Dawley rats, each weighing 250-300 g were obtained from the 
Laboratory Animal Center, Singapore. The Institutional Animal Care and Use 
committee of laboratory animal centre, National University of Singapore, Singapore 
approved the animal experiments. Rats were housed in metabolic stainless steel cages 
individually in an air-conditioned room (23 ± 1°C). They were maintained on 12 h 
light/dark cycle for three days before the experiment. The animals had access to food 
(rat cubes) and water ad libitum during the experimental period, but fasted overnight 
before oral administration of warfarin and 4h after the administration.  
 
3.3.3.1. Preparation of citrate buffer diluted plasma 
 
Venous blood was obtained from the orbital sinus of rats by puncturing with 
siliconized capillary tube. First two drops of blood were discarded. Citrate-diluted 
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plasma was prepared as per the method established previously in our laboratory (102). 
Not less than 50 μl of blood was collected into micro centrifuge tube with 250 μl 
sodium citrate solution. Subsequently, hematocrit blood sample was obtained by 
introducing one end of the heparinized microhematocrit capillary tube into the orbital 
sinus of the eye. Both micro centrifuge tube & microhematocrit capillary tube were 
weighed on an analytical balance immediately. Length in mm of blood in the 
microhematocrit tube was recorded. Following equations were used to calculate the 
volume of blood collected into the micro centrifuge tube: 
Gravity (mg/ml) = (W2-W1) × c/L 
c - a coefficient determined by filling microhematocrit tube with a known volume of 
distilled water, measuring the length of the water column obtained & then calculating 
the ratio of the length to the volume. 
Volume (μl) of blood received into the micro centrifuge tube with anticoagulant 
solution is given by, volume = (W2-W1)/gravity. 
W- weight (in mg) of the micro centrifuge tube containing sodium citrate solution 
(250 μl) 
 
After calculating the accurate volume of blood, extra sodium citrate solution was 
added to make up 1:6 dilution of the whole blood. The citrate-diluted blood was 
centrifuged for 10 min at 3000 rpm, plasma was separated and used for the One Stage 
Prothrombin Time test. Serum was prepared from about 400 μl of blood obtained 
without citrate. Concentration of the warfarin enantiomers in the serum was analyzed 
by normal phase HPLC method. 
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3.3.4. Chemical analysis 
 
The stereospecific HPLC method established by Banfield, C. and Rowland, M. 1984 
(65), was used for the chemical analysis. The S- and R- enantiomers of warfarin in the 
serum sample were separated by first converting them into diastereomeric esters with 
carbobenzyloxy L-proline and further separating on HPLC system. The effluent from 
the column was mixed with postcolumn n-butylamine for aminolysis to break the 
esters as warfarin loses its fluorescence due to the ester formed at 4-hydroxyl group. 
The resulting fluorescent enantiomers were detected on-column fluorimetrically. 
 
3.3.5. Estimation of anticoagulation 
 
Neoplastine reagent was prepared by reconstituting freeze-dried thromboplastine 
powder (Reagent 1) in 2.5 ml of the given aqueous solvent (Reagent 2) just before 
use. The test protocol of the machine was set to sample 100 μl of citrate-diluted 
plasma (102) and mix with 50 μl of the Neoplastine reagent automatically. The 
program of the machine allows the sampled plasma to be incubated for 180 s at 37°C 
before the addition of the reagent. The maximum reaction time was adjusted to 600 s. 
The clotting time in seconds (PT) as end point was read directly from the touch screen 
of the machine. The precision was tested by using blank pooled plasma at different 
dilutions within a range of 100-15% and was found to be acceptable (RSD 0.32-
5.31%). 
 
3.3.6. Animal study protocol 
 
Two groups of male Sprague-Dawley rats (n = 8 per group), in a parallel design, 
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received rutin (1 g in 1% CM-cellulose/kg) and an equal volume (5 ml/kg) of 1% 
CM-cellulose (as the control), respectively, by oral intubation, once a day for eight 
consecutive days. On day 5, each rat received a single oral dose of racemic warfarin 
(1.5 mg/kg, dose volume = 5 ml/kg) by oral intubation. Blood samples were collected 
from each rat prior to, and 1, 3, 6, 12, 24, 48, 72 and 96 h after warfarin 
administration. About 400 μl of blood obtained without anticoagulation was 
centrifuged (10 min at 3000 × g) to separate serum. Serum samples obtained were 
then stored at −20°C before HPLC analysis. For the subsequent anticoagulant effect 
measurement, 50 μl of each blood sample was used for diluted plasma preparation 
according to the established procedure (102). 
 
3.3.7. Data Analysis 
3.3.7.1. Pharmacodynamic analysis 
 
The PT (in seconds) obtained was converted to prothrombin complex activity (PCA) 
(as percentage of normal activity) using the calibration curve performed (103) as 
explained below. The pooled plasma from untreated rats was diluted to different 
dilutions ranging from 100 to 15 % (PCA), with 100 % being the undiluted plasma 
and the corresponding PT values were measured. The calibration curve was plotted 
using PT values (in seconds) on the y-axis & PCA % on the x-axis. The calibration 
equation thus obtained was used to calculate the PCA % corresponding to each of the 
PT value measured in the study. The minimum value of PCA (PCAmin), time to 
achieve PCAmin (tPCA,min) and the total area under the PCA–time curve from time zero 
to 96 h after warfarin (PCA AUC0-96), obtained using the linear trapezoidal rule, were 
used to assess the degree of blood coagulability (102). PCAmin corresponds to the 
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maximum anticoagulation achieved and the tPCA,min represents the time to reach 
maximum anticogulation.   
 
3.3.7.2. Pharmacokinetic analysis 
 
WinNonlin (version 1.1) iterative curve-fitting program based on nonlinear regression 
analysis (Scientific Consulting Inc., Lexington, KY, USA) was used to estimate 
various pharmacokinetic parameters (104). The time-profiles of the S- and R-
enantiomers of warfarin following its oral administration to rats were adequately 
described using the one-compartment open model with first-order absorption and 
elimination. The administered dose of warfarin was divided by two to obtain the 
equivalent enantiomeric dose (105).  The rate and extent of warfarin absorption were 
assumed to be non-stereoselective and complete, respectively (105, 106). 
 
The peak serum concentration (Cmax) for each enantiomer of warfarin and the 
corresponding time of its occurrence (tmax) were obtained by visual inspection of the 
serum concentration–time curves. The absorption rate constant (ka), elimination half-
life (t1/2), total serum clearance (CL) and apparent volume of distribution (Vd) were 
obtained from the nonlinear regression analysis. The total area under serum 
concentration-time curve from time zero to infinity (AUC0-∞) was calculated using 
linear trapezoidal rule. 
 
3.3.7.3. Statistical analysis 
 
The Statistical Package for the Social Sciences (SPSS 11.0 for windows, SPSS Inc., 
USA) was used for the data analysis. Data were expressed as mean ± standard 
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deviation (SD). Comparisons of means of related samples and from two independent 
groups were made using the Student’s paired-samples and independent-samples t-




3.4.1. Warfarin pharmacokinetics 
 
The mean serum concentration-time profiles of the S- and R- enantiomers of warfarin 
after oral administration of a single dose of the racemic drug (1.5 mg/kg) in the 
presence and absence of rutin are shown in Fig. 3.1. Rutin treatment significantly 
increased both S- and R-warfarin serum levels initially compared to control group. 
Subsequently during the elimination phase both the enantiomer levels were lower 
with respect to that in control animals. The difference between the two groups in 
enantiomer levels was statistically significant at 3 (p<0.01), 6 (p<0.05) and 48 h 
(p<0.05) time-points in case of S-warfarin and 3 (p<0.01) and 48 h (p<0.05) for R-
warfarin. The serum concentration profile of S- warfarin in control and rutin treated 
groups after WinNonlin curve fitting is shown in Fig. 3.2 (a,b) and that of R- warfarin 
are shown in Fig. 3.3 (a,b). 
 
Estimates of pharmacokinetic parameters between the two groups are summarized in 
Table 3.1. With regard to those describing absorption kinetics, rutin treatment 
increased the S- and R- warfarin Cmax values (by 71.3 and 59.7%, respectively; p<0.01 
and p< 0.05) while tended to shorten the corresponding tmax values (by 27.3 and 
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Figure 3.1  Time courses of total serum concentrations (mean ± S.D.) of S- and R- 
enantiomers of warfarin following a single oral administration of racemic dose (1.5 
mg/kg) to rats alone (receiving 1% CM-cellulose, 5 ml/kg daily, as the control) and 
during 8-day treatment with rutin (1 g in 1% CM-cellulose, 5 ml/kg daily).  
 
* p < 0.05 comparing the control group with rutin treatment group.  
























Figure 3.2  S- warfarin (mean) curve fitting for (a) control and (b) rutin treated rats 
in single dose study using WinNonlin. Control rats received 1% CM-cellulose, 5 
ml/kg, daily and rutin group was given 1 g rutin in 1% CM-cellulose, 5 ml/kg daily 
for eight consecutive days. On day 5, each rat received a single oral dose of racemic 
warfarin (1.5 mg/kg, dose volume = 5 ml/kg). One compartment open model with no 
lag time, with 1st order absorption and 1st order elimination, and with user specified 
initial parameters and bounds was used to select the best fitting curve. The circular 

























Figure 3.3  R- warfarin (mean) curve fitting for (a) control and (b) rutin treated rats 
in single dose study using WinNonlin. One compartment open model with no lag 
time, with 1st order absorption and 1st order elimination, and with user specified initial 
parameters and bounds was used to select the best fitting curve. The circular points 




Table 3.1  Estimated pharmacokinetic parameters of (S)- and (R)- enantiomers of 
warfarin after a single oral administration of racemic drug (1.5 mg/kg) to rats in the 
absence and presence of rutin 
 
Control Rutin Parameter 
S-warfarin R-warfarin S-warfarin R-warfarin 
Cmax (μmoles/L) 10.1 ± 2.4 7.7 ± 2.3 a 17.3 ± 4.8 c 12.3 ± 4.1 d 
tmax (h) 5.30 ± 3.1 4.66 ± 2.2 3.85 ± 1.8 3.37 ± 1.4 
AUC0-∞  
(μmoles/L·h) 
304.9 ± 64.5 149.4 ± 24.3 a 302.1 ± 125.2 157.0 ± 50.3 
ka (h-1) 0.637 ± 0.63 0.698 ± 0.55 0.857 ± 0.60 0.938 ± 0.79 
t1/2 (h) 15.3 ± 2.1 10.1 ± 1.5 a 8.6 ± 2.6 c 6.0 ± 2.0 c 
Vd (L/kg) 0.183 ± 0.044 0.242 ± 0.053 b 0.107 ± 0.028 c 0.137 ± 0.031 c
CL (ml/kg/h) 8.30 ± 1.8 16.67 ± 2.7 a 9.23 ± 3.4 16.83 ± 4.9 
 
Values are mean ± S.D. (n = 8) 
Cmax, maximum serum concentration; tmax, peak time.; AUC0-∞, total area under serum 
concentration-time curve from time zero to infinity; ka, absorption rate constant; t1/2, 
elimination half life; Vd, apparent volume of distribution; CL, total serum clearance.   
 
a p < 0.01 comparing S- warfarin with R- warfarin in control group 
b p < 0.05 comparing S- warfarin with R- warfarin in control group 
c p < 0.01 comparing the control group with rutin treatment group      





(by 34.5 and 34.4%, respectively) in the rutin treatment group compared to the control 
group.  With regard to parameters describing disposition kinetics, rutin treatment 
significantly reduced the Vd values (by 41.5 and 43.4%, respectively) and t1/2 values 
(by 43.8 and 40.6%, respectively) of both S- and R- warfarin (p < 0.01). There was no 
significant difference in AUC and CL for either S- or R- warfarin between the control 
and rutin co-administration groups. 
 
3.4.2. Effect of rutin treatment on warfarin anticoagulation  
 
The basal mean prothrombin times (PT0) between the control and rutin treatment 
groups were similar either with CM-cellulose (1%, 5 ml/kg daily) or rutin (1 g in 1% 
CM- cellulose, 5 ml/kg daily) treatment for four days. Table 3.2 shows the 
pharmacodynamic parameters after acute dose of warfarin (1.5 mg/kg) in rutin treated 
and control rats. Rutin treatment appeared to reduce mean PCAmin (by 74.3%) and 
tPCA,min (by 30.8%, p < 0.05) compared to the control group. The mean PCA AUC0-96h 
value of rutin treatment group was significantly higher (by 31.3%, p < 0.05) than that 
of control rats. With the warfarin administration, the PT values increased in all the 
animals as shown in Fig. 3.4. Recovery from this hypoprothrombinaemia was faster 
with rutin treated animals as lower PT (and higher PCA) values were observed at both 
48 h and 72 h (p < 0.05) post warfarin dose in the treatment group compared to that in 




Rutin, as a constituent as well as in pure form, is widely used in complementary and
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Table 3.2  Estimated pharmacodynamic parameters (mean± S.D.) following a single 
oral administration of racemic warfarin (1.5 mg/kg) to rats alone (control) and during 
rutin treatment 
 
Parameter Control Rutin 
PT0 (s) 43.9 ± 8.5 41.5 ± 11.3 
PCAmin (% normal) 14.4 ± 2.8 3.7 ± 3.0 
PT AUC0-96h (s·h) 19130.3 ± 4239.3 15676.7 ± 2497.2 
PCA AUC0-96h (% normal·h)  4431.3 ± 1271.8 5818.9 ± 767.6 a 
tPCA,min (h)     39.0 ± 12.4 27.0 ± 8.5 a 
 
PT0, basal prothrombin time at time zero; PCAmin, minimum prothrombin complex 
activity; PT AUC0-96h, area under PT-time curve from time zero to last sampling point; 
PCA AUC0-96h, area under PCA-time curve from time zero to last sampling point 
(96h); tPCA,min, time to achieve PCAmin. 
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Figure 3.4  Changes in prothrombin time (PT in s) and prothrombin complex 
activity (PCA in percent of normal) with time following a single oral dose of racemic 
warfarin (1.5 mg/kg) to rats treated with and without rutin. Values are expressed as 
mean ± SD (n = 8).  
 
* p < 0.05 comparing the control group with rutin treatment group. ** p < 0.01 
comparing the control group with rutin treatment group. 
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alternative medicines and numerous health supplements. Apart from the 
cardiovascular benefits, rutin is also shown to lower plasma lipids and hepatic 
cholesterol levels (86). Rutin has been reported to counteract dicoumarol in rats (107). 
When rutin was coadministered orally with dicoumarol, PT was shorter compared to 
that with dicoumarol alone (107). As rutin combined with warfarin is reported to be 
beneficial in limb salvage and survival in patients with severe critical leg ischemia 
(23), coadministration of the two drugs clinically is a promising option. But warfarin 
with low therapeutic index and being known to interact with various drugs and herbs, 
such as Danshen (108), Ginseng (49), St. John’s wort (109), potential drug interaction 
needs to be carefully considered. Our study has revealed some evidence of interaction 
between rutin and warfarin in rats. 
 
Rats fed orally with rutin at a dose of 1 g/kg body weight for 22 days reportedly 
showed no toxic effects (97). Thus the rutin dose of 1 g/kg body weight, much higher 
than the normal dietary intake in man, was selected for our study to maximize the 
potential interactions, if any. Rats were treated with rutin orally for four days before 
administering a single dose of warfarin. This could possibly mimic a clinical case of 
starting warfarin in a patient who has been on a diet rich in rutin and also on dietary 
supplements and herbal remedies with rutin as one of the constituents. The rats were 
monitored closely throughout the study and all the animals were found to tolerate the 
treatment and the repeated blood sampling well. 
 
In agreement with the initial assumption (105, 106), the present study showed no 
significant stereoselective difference in the rate of absorption of warfarin enantiomers 
in control animals receiving CM-cellulose only. The peak serum concentration (Cmax) 
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achieved with S-warfarin was significantly higher than that of R-warfarin. It is known 
that R-warfarin is eliminated faster in rats and slower in man compared to S-warfarin 
elimination kinetics (48). Consistent with literature reports (48, 110), significantly 
lower AUC, higher clearance and shorter elimination half-life for R-warfarin, in 
comparison to S-warfarin, were observed in control rats. Also, the Vd value of R-
warfarin was larger than that of S-warfarin, due possibly to a higher binding affinity 
to albumin for the latter (8, 48). The tmax values of both the enantiomers were found to 
be slightly longer compared to those obtained previously in our laboratory in similar 
experiments (104, 111). This could be due to the use of CM-cellulose as a vehicle in 
the present study, though it needs to be verified further. It is also known that the 
presence of food can slow the rate of absorption of warfarin without affecting its 
bioavailability (8). 
 
There was no significant difference in mean PT values between the rutin treatment 
and control groups prior to warfarin dosing (PT0). Thus after four days of treatment, 
rutin by itself showed no effect on blood coagulation. (This was further supported by 
designing a study of effects of rutin on blood coagulation in the absence of warfarin. 
Rutin treatment alone showed no significant effect on blood coagulation compared to 
that of control). When a single dose of warfarin was administered to both the groups, 
warfarin caused hypoprothrombinaemia in all the animals, represented by increased 
PT (decreased PCA). The degree of hypoprothrombinaemic response was enhanced at 
24 h only, but was reduced at all other time-points, with concurrent rutin 
administration. As a result, rutin treatment increased the total area under the PCA-
time curve from 0 to 96 h post warfarin. This indicated an overall reduction in the 
anticoagulation response to warfarin. It was also interesting to note that the recovery 
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from warfarin anticoagulation was found to be much faster in the presence of rutin. 
The difference in PT (and PCA) between the two groups was especially significant at 
72 h post warfarin dose. 
 
Similarly, pharmacokinetic parameters of S- and R-warfarin showed a trend of 
interaction in the presence of rutin. There was an initial increase followed by lower 
levels of both the enantiomers in rutin treated rats. S-warfarin levels significantly 
differed between the two groups at 3, 6 and 48 h time-points and R-warfarin levels at 
3 and 48 h after warfarin dose. The initial increase in serum levels of S-and R-
warfarin is intriguing. Rapid absorption of a drug can lead to a higher peak 
concentration and shorter peak time. Our results showed an apparently higher ka and 
shorter peak time with rutin treatment, though not statistically significant. An increase 
in R-and S-warfarin levels would be expected, as quercetin, the aglycone of rutin, has 
been shown to inhibit in vitro human CYP3A4 and CYP2C9 (6), the hepatic 
microsomes responsible for the metabolism of R- and S-warfarin, respectively (11). 
 
In vitro studies using specific CYP enzymes may be needed to shed more light on this 
interaction. Typically, the inhibitory constant, Ki, for the inhibitor drug is used to 
determine the inhibition efficiency (112). However, Ki value needs to be estimated 
very accurately to successfully predict from in vitro data, whether a drug inhibits CYP 
enzymes in vivo or not (112). If not, the prediction of in vivo drug interactions may 
not be very conclusive (112). As such it has been reported that in vitro and in vivo 
data on CYP isoform modulation could yield contradictory results (113, 114, 115, 
116). Estimation of warfarin metabolites in urine is also important to understand the 
effect of rutin on warfarin. It can provide valuable insight into the metabolism and 
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clearance of warfarin and potential metabolic interactions with rutin, if any.  . 
 
Rutin appeared to have no effect on the total serum clearance values of R- and S-
warfarin.  However, the apparent volumes of distribution of the two enantiomers were 
significantly lower in case of the rutin group.  Hence, shorter elimination half-life 
values of S- and R-warfarin were observed with rutin treated rats compared to that of 
control. This could have been responsible for the observed lower levels of S- warfarin 
and possibly the faster recovery of PT with rutin treatment. Quercetin and related 
flavonoids have been reported to bind (99.1-99.4%) almost exclusively and strongly 
to human serum albumin in vitro (24) as well as rodent albumin (14). Both warfarin 
and quercetin bind to the IIA domain of albumin (117, 118) and quercetin is shown to 
be displaced by large excess of warfarin, although not competitively (24, 94). Using 
fluorescence spectroscopy these researchers studied albumin binding of quercetin in 
the presence of large excess of warfarin but individual warfarin enantiomers were not 
quantitated. In our study, as total serum clearance was not altered much, rutin 
administered in large excess could have affected the serum and tissue protein binding 
of warfarin. Thus, further analysis of protein binding is needed to be carried out to 




The single dose study reveals possible pharmacokinetic drug interactions between 
rutin and a single dose of warfarin. Rutin treatment increased the Cmax and reduced the 
t1/2 and Vd values of both S- and R- warfarin significantly and lowered the serum 
levels of both the enantiomers in the elimination phase compared to the control group. 
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Rutin treatment also resulted in a faster recovery from the hypoprothrombinaemia 
caused by warfarin. Thus, due to the risk of potential interactions between the two 
when co-administered, extra care must be taken to exclude high levels of rutin 
aglycone and conjugates in patient blood before starting warfarin therapy. In addition, 
if the patient has been stabilized on warfarin with concomitant use of rutin or 
quercetin, precaution should be taken to avoid sudden suspension of rutin as it may 
affect warfarin levels fatally. Therapeutic monitoring of warfarin is extremely 
important in this scenario and warfarin dose regimen needs to be adjusted 
accordingly. 
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Warfarin is used to treat various cardiovascular disorders and generally administered 
for a very long period. Warfarin drug interactions are clinically relevant since an 
interaction leading to increased action may cause hemorrhage and decreased action 
may cause reduced anticoagulation (115). With the initiation of warfarin therapy, 
notable and stable anticoagulation is achieved only after the existing vitamin K-
dependent clotting factors are removed from the circulation by clearance (37, 61). 
Due to the long half-life of some of the coagulation factors, complete antithrombotic 
effect is not achieved for several days (37). But the PT may be prolonged sooner 
because of the rapid reduction of clotting factors with shorter half-life (37). Generally, 
2 to 7 days are required to reach this steady state of anticoagulation depending on the 
dose used (61). However, in case of non emergency conditions, such as chronic stable 
atrial fibrillation, a maintenance dose of 4-5 mg/day may achieve steady-state 
anticoagulant effect in about 14 days (61). Thus with multiple dosing of warfarin and 
longer duration of treatment, introduction of an interacting constituent can have 
serious implications as warfarin has a very narrow therapeutic index.  
 
It is known that although target anticoagulation (PT/INR) was maintained carefully in 
patients, a brief change in drug compliance or diet may precipitate fatal bleeding or 
clotting (115, 119). For example, when an herbal preparation with antiplatelet activity 
is introduced in a patient on chronic anticoagulation with stable PT/INR values, 
resulting interaction can lead to bleeding complications (119). Some of the clinical 
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reports of fatal interactions between long term multiple doses of warfarin and herbs 
are compiled in Table 4.1 (119).  
 
With a small therapeutic window of warfarin, such interactions are possible due to 
various reasons like, inherent anticoagulant/antiplatelet activities of the herbs/diet or 
effects on the pharmacokinetics of warfarin (119). Furthermore, due to its elimination 
half-life range of 25 to 60 hours (37), warfarin may take longer time before its plasma 
concentrations and anticoagulant effects come back to therapeutic levels. It is known 
that 3.5 to 5 half-lives are required to reach a steady state whenever there is a change 
(addition or deletion) in dose. So it is important to understand the mechanisms of 
potential interactions, not only with single dose, but also with multiple doses of 
warfarin and a longer treatment regimen. 
 
Understanding and managing warfarin interactions with complementary and 
alternative medicines (CAM) is a challenge as relevant details such as active 
constituents, efficacy and adverse effects of most of these medicines are scarce. 
Herbal formulas such as garlic preparations may vary in the amount of their active 
constituents depending on the mode of preparation (120). Many of the multivitamins 
and herbal drugs can potentially affect the therapeutic benefits of warfarin (121) 
(Table 1.6). It was reported by Kurnik, D. et al 2003 (121) that 3 different patients on 
warfarin experienced sub- or supratherapeutic INR levels with initiation or cessation 
of a daily dose of multivitamin preparation containing vitamin K (121). As such the 
levels of these multivitamins in blood may be insignificant to affect but when given to 
patients on anticoagulation, vitamin K-containing multivitamins can inhibit the 
beneficial effects of warfarin (121).  
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Table 4.1  Clinical case reports of complications arising due to interactions between 





Herb used dosage complication 
32/Female * Prolonged post-operative 
bleeding 




* Postoperative bleeding 
70/Male 80 mg/day Spontaneous hyphema 
33/Female 120 mg/day Spontaneous subdural 
hematoma 
72/Female 150 mg/day Spontaneous subdural 
hematoma 
78/Female * Intracerebral hemorrhage 
61/Male 
Ginkgo Biloba 
160 mg/day Subarachnoid hemorrhage 
61/Male Quiling gao 1 can/day a Mucosal bleeding 
25/Female Herbal tea * menometrorrhagia 
* Devil’s claw  * Purpura 
48/Female * a Increased response to 
warfarin 




* a Pleural hemorrhage 
47/Male 3 capsules/day a Reduced response to 
warfarin 
44/Female Face cream Vaginal bleeding 
72/Female 
Ginseng 
200 mg Vaginal bleeding 
 
* Not applicable 
 
a Patient on chronic anticoagulation therapy with warfarin 
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In the next part of the study, rats were treated with daily doses of warfarin for five 
days before administering rutin. This was designed to possibly mimic a clinical case 
of a patient stabilized and responding well to a warfarin treatment regimen and taking 
subsequent rutin unknowingly along with warfarin.     
 
As rutin is shown to have the potential to interact with single dose of warfarin, it was 
imperative to see if by itself rutin had any action on the blood coagulation in rats. 
Quercetin and rutin are strong anti-platelet and antithrombotic agents in vivo though 
in vitro potency is modest (122). Their antithrombotic property could be due to a 
combination of the anti-oxidant action and the ability to bind to platelet membranes 
(122). Thus in the next set of experiments rutin was evaluated alone, in the absence of 
warfarin, for its effect on blood coagulation, if any. Rats were treated with rutin orally 





The objective was to study the effect of introduction of rutin on pharmacokinetic and 
pharmacodynamic properties of warfarin at steady state levels in rats. Concentrations 
of each of the warfarin enantiomers were quantitatively estimated in serum by HPLC 
assay and pharmacokinetic parameters calculated. Also the effect on warfarin 
anticoagulation was measured.  
 
Further experiments were designed to study the effect of rutin alone on coagulability 
in rats in the absence of warfarin. The effect on coagulation was evaluated by 
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measuring prothrombin time and PCA (as percentage of normal prothrombin complex 
activity). 
 
4.3. MATERIALS AND METHODS 
4.3.1. Apparatus 
 
The HPLC system for the assay of warfarin enantiomers was as follows: A solvent 
delivery system (LC-10AT, Shimadzu), sample injector with standard sample loop 
(20 μl), a fluorescence detector (RF-10AXL, Shimadzu), a communication bus 
module (CBM101, Shimadzu), a computer and a workstation (Class-CR10, 
Shimadzu). The chromatographic conditions for isocratic normal phase HPLC were as 
follows: A stainless steel column (250 × 4 mm) packed with silica (MAXSIL 10 
silica, 10 micron, Phenomenex, USA) maintained at 23°C ambient temperature, was 
used for the separation. Mobile phase of a mixture of ethyl acetate/n-hexane 
(22.5:77.5) was run at a flow rate of 0.8 ml/min. Bed reactor (stainless steel column 3 
mm i.d., 25 cm) packed with glass beads (40 μm) was used for the post column 
aminolysis. Butylamine/methanol (1:1) was pumped as the post column reagent at a 
flow rate of 0.4 ml/min. The effluent from the column was detected by excitation at 
313 nm and emission at 400 nm using a fluorescence detector. For the prothrombin 
time (PT) test, fully automated coagulation analyzer (Sysmex automated blood 
coagulation analyzer, CA 530, Sysmex Corporation, Kobe, Japan) was used. 
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4.3.2. Animals and sampling method 
 
Adult male Sprague-Dawley rats, each weighing 250-300 g were obtained from the 
Laboratory Animal Center, Singapore. The animal experiments were approved by the 
Institutional Animal Care and Use Committee of laboratory animal centre, National 
University of Singapore, Singapore. Rats were housed in metabolic stainless steel 
cages individually in an air-conditioned room (23 ± 1°C). They were maintained on 
12 h light/dark cycle for three days before the experiment. The animals had access to 
food (rat cubes) and water ad libitum during the experimental period, but fasted 
overnight before oral administration of warfarin and 4h after the administration. Rat 
cubes, the standard diet for laboratory animals fortified with vitamins and minerals, 
purchased from Glen Forest Stockfeeders, Australia.  
 
4.3.2.1. Preparation of citrate buffer diluted plasma 
 
Venous blood was obtained from the orbital sinus of rats by puncturing with 
siliconized capillary tube. Citrate-diluted plasma was prepared as per the method 
established (102). The citrate-diluted blood was centrifuged for 10 min. at 3000 rpm, 
plasma was separated and used for the One Stage Prothrombin Time test. Serum was 
prepared from about 400 μl of blood obtained without citrate. Concentration of the 
warfarin enantiomers in the serum was analyzed by normal phase HPLC method. 
 
4.3.3. Chemical analysis 
 
The stereospecific HPLC method established by Banfield, C. and Rowland, M. 1984 
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(65), was used for the chemical analysis. The S- and R- enantiomers of warfarin in the 
serum sample were separated by first converting them into diastereomeric esters with 
carbobenzyloxy L-proline and further separating on HPLC system. The effluent from 
the column was mixed with postcolumn n-butylamine for aminolysis. The resulting 
fluorescent enantiomers were detected on-column fluorimetrically. 
 
4.3.4. Estimation of anticoagulation 
 
Neoplastine reagent was prepared by reconstituting freeze-dried thromboplastine 
powder (Reagent 1) in 2.5 ml of the given aqueous solvent (Reagent 2) just before 
use. The test protocol of the machine was set to sample 100 μl of citrate-diluted 
plasma (102) and mix with 50 μl of the Neoplastine reagent automatically. The 
maximum reaction time was adjusted to 600 s. The clotting time in seconds (PT) as 
end point was read directly from the machine. The precision was tested by using 
blank pooled plasma at different dilutions within a range of 100-15% and was found 
to be acceptable (RSD 0.32-5.31%). 
 
4.3.5. Animal study protocol 
4.3.5.1. Multiple dose study 
 
Male Sprague-Dawley rats were divided randomly into control and treatment groups 
(n = 6 per group). For the first five days animals from both the groups received oral 
warfarin (0.15 mg/kg/day, dose volume = 5 ml/kg) daily to reach a steady state. On 
the sixth day, along with warfarin, control rats were also given CM-cellulose (1% 
w/v) (5 ml/kg) orally. In a parallel design, treatment group received rutin (1 g in 1 % 
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CM-cellulose/kg) at a dose of 5 ml/kg body weight apart from the warfarin dose. 
Daily dosing of warfarin and rutin/CM-cellulose, sodium salt was continued till 96 h 
post the first rutin dose. Blood samples were collected from each rat prior to, and 24, 
48, 72, 96, 120, 144 and 168 h after the administration of the first dose of rutin. 
Plasma and serum samples were prepared (102) and separated by centrifugation (10 
min at 3000 X g) and stored at –20°C until analysis.  
 
4.3.5.2. Control rutin treatment study in the absence of warfarin  
 
This treatment schedule was designed to study the effect of rutin alone on blood 
coagulation in rats. One group of male Sprague-Dawley rats (n = 6) was treated with 
rutin (1 g/kg/day, dose volume = 5 ml/kg body weight) for 5 days. The control rats (n 
= 6) received oral CM-cellulose (1% w/v) (5 ml/kg) for the same period. Blood 
samples were collected from each rat prior to, and 24, 48, 72, 96, 120, 144 and 168 h 
after the first dose of rutin. Plasma samples were prepared by appropriate dilutions of 
the blood with citrate buffer (102), centrifuged (10 min at 3000 X g), separated and 
stored at –20°C until before the analysis. 
 
4.3.6. Data analysis 
4.3.6.1. Pharmacodynamic analysis 
 
The PT (in seconds) obtained was converted to prothrombin complex activity (PCA) 
(as percentage of normal activity) using the calibration curve performed (103). The 
minimum value of PCA (PCAmin) was used to assess the degree of blood coagulability 
(111). PCAmin corresponds to the maximum anticoagulation achieved. 
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4.3.6.2. Pharmacokinetic analysis 
 
The time-profiles of the S- and R-enantiomers of warfarin following its oral 
administration to rats were evaluated. The administered dose of warfarin was divided 
by two to obtain the equivalent enantiomeric dose (105). The minimum serum 
concentration during steady state (Cmin) for each enantiomer of warfarin was obtained 
from the serum concentration–time curve by taking the mean of all the trough 
concentration values during the steady state. WinNonlin (version 1.1) iterative curve-
fitting program (Scientific Consulting Inc., Lexington, KY, USA) was used to 
estimate various pharmacokinetic parameters (104). The apparent volume of 
distribution (Vd) and absorption rate constant (ka or k01) obtained from the single dose 
study were used as a basis for curve fitting. Also the elimination rate constant (k or 
k10) was calculated from the terminal phase of the serum concentration-time curve for 
each animal and the value was used as the initial parameter for curve fitting along 
with Vd and ka. One compartment open model with no lag time, with 1st order 
absorption and 1st order elimination, and with user specified initial parameters and 
bounds was used to select the best fitting curve for each animal data and subsequent 
PK parameters. Elimination half life (t1/2) was estimated from the k value. Steady state 
clearance value was estimated using the formula CLss = (R0/Cmin) where CLss is the 
clearance value associated with minimum serum concentration at steady state (Cmin) 
and R0 is the dosing rate. The apparent volume of distribution (Vss) associated with 
minimum serum concentration at steady state is calculated using the equation Vss = 
CLss/k. 
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4.3.6.3. Statistical analysis 
 
The Statistical Package for the Social Sciences (SPSS 11.0 for windows, SPSS Inc., 
USA) was used for the data analysis. Data were expressed as mean ± standard 
deviation (SD). Comparisons of means of related samples and from two independent 
groups were made using the Student’s paired-samples and independent-samples t-
tests, respectively. A p-value of less than 0.05 was taken as statistically significant. 
 
4.4. RESULTS 
4.4.1. Steady-state pharmacokinetics of warfarin 
 
Fig. 4.1(a,b) illustrates the time course of mean (± SD) serum concentrations of S- 
and R- enantiomers of warfarin at steady state in the presence and absence of rutin. 
Warfarin treatment for the first five days in both groups resulted in similar serum 
levels of both the enantiomers. With rutin treatment, S- warfarin levels were 
significantly (p < 0.05) reduced at 72 and 96 h post first dose of rutin compared to that 
of control group. R- warfarin levels also declined in a similar pattern though the 
difference between the control and treated groups was not statistically significant. 
After the last dose of warfarin at 96 h, serum levels of both the enantiomers reduced 
by the first-order elimination kinetics. But S- warfarin was eliminated faster compared 
to R- warfarin. These results showed a similar trend to single dose study results with 
respect to the elimination phase. Steady state trough serum concentrations of S-
warfarin in control and rutin treated groups after WinNonlin curve fitting are shown 
in Fig. 4.2 (a,b) and that of R- warfarin are shown in Fig. 4.3 (a,b). These WinNonlin 
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Figure 4.1  Time profiles of (a) S- and (b) R- warfarin concentrations (mean ± S.D.) 
in serum after multiple doses of warfarin (0.15 mg/kg body weight) in control and 
rutin treated rats (n = 6). Animals from both the groups received oral racemic warfarin 
daily, for initial five days (blood samples were not collected/analyzed during this 
period). From “0” h, along with warfarin, control rats were given daily CM-cellulose 
(1% w/v) (5 ml/kg) and treatment group received rutin (1 g in 1 % CM-cellulose/kg) 
(5 ml/kg body weight, orally for 96 h.  




















Figure 4.2  Mean S- warfarin curve fitting for (a) control and (b) rutin treated rats 
using WinNonlin. Animals from both the groups received oral racemic warfarin (0.15 
mg/kg body weight) daily, for initial five days (blood samples were not 
collected/analyzed during this period). From 120 h post 1st dose of warfarin, along 
with warfarin, control rats were given daily CM-cellulose (1% w/v) (5 ml/kg) and 
treatment group received rutin (1 g in 1 % CM-cellulose/kg) (5 ml/kg body weight, 
orally for 96 h. One compartment open model with no lag time, with 1st order 
absorption and 1st order elimination, and with user specified initial parameters and 
bounds was used to select the best fitting curve. The circular points indicate observed 























Figure 4.3  Mean R- warfarin curve fitting for (a) control and (b) rutin treated rats 
using WinNonlin. One compartment open model with no lag time, with 1st order 
absorption and 1st order elimination, and with user specified initial parameters and 
bounds was used to select the best fitting curve. The circular points indicate observed 
S- warfarin levels and the line connecting those shows predicted levels. 
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(marked as circular points in the graph) change from trough values to peaks between 
doses at steady state. Also the terminal elimination phase shows a linear pattern.  
 
Pharmacokinetic profiles between the two groups for both the enantiomers of warfarin 
are compared in Table 4.2. Rutin treatment significantly reduced the minimum serum 
concentration value during steady state, Cmin, (by 26.67 %) of S- warfarin (p < 0.05) 
compared to that of control group. R-warfarin minimum serum concentration levels 
during steady state reduced to a small extent (10.82 %) without any statistical 
significance. With rutin treatment, elimination half-life of S- warfarin reduced by 41 
% but the difference was not statistically significant. However the elimination half-
life of R- warfarin remained almost unchanged between control and rutin treated 
animals.  
 
As the coefficient of variation of estimation of Vd and CL values from the WinNonlin 
curve fitting was very high, we based the CLss and Vss estimation on minimum serum 
concentration value at steady state (Cmin). CLss for S- warfarin increased with rutin 
treatment (by 31.1 %) compared to that of control group without statistical 
significance. However, CLss for R- warfarin was almost unchanged between control 
and rutin treated groups. Rutin treatment decreased the Vss values of S– warfarin (by 
36.11 %) but the decrease was not statistically significant. These results were similar 
to that of single dose study. 
 
4.4.2. Effect of rutin treatment on warfarin anticoagulation at steady state 
 
The time course of changes in PCA after multiple doses of warfarin with or without  
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Table 4.2  Pharmacokinetic parameters of control (treated with CM-cellulose only) 
and rutin treated (rutin in CM-cellulose) rats with respect to S- and R- warfarin after 
treatment with multiple doses of racemic warfarin (0.15 mg/kg body weight/day) 
orally. 
 
Control Rutin treated Parameter 
S- warfarin R-warfarin S- warfarin R-warfarin 
Cmin (μmol/L) 3.30 ± 0.81 1.57 ± 0.52 a 2.42 ± 0.51 c 1.40 ± 0.38 d 
Elimination t1/2 
(h) 13.35 ± 2.27 9.61 ± 2.32 7.87 ± 2.35 9.45 ± 0.87 e 
Vss (L/kg)* 0.072 ± 0.05 0.128 ± 0.07 b 0.046 ± 0.018 0.136 ± 0.031 d 
CLss 
(ml/kg/h)* 3.31 ± 1.17 7.167 ± 2.63 a 4.34 ± 0.87 7.55 ± 1.48 d 
 
Values are mean ± S.D. (n = 6) 
Cmin, minimum serum concentration during steady state; t1/2, elimination half life; Vss, 
apparent volume of distribution associated with minimum serum concentration during 
steady state; CLss, total serum clearance associated with minimum serum 
concentration at steady state.   
 
* based on the minimum serum concentration at steady state  
a p < 0.01 comparing S- warfarin with R- warfarin in control group 
b p < 0.05 comparing S- warfarin with R- warfarin in control group 
c p < 0.05 comparing the control group with rutin treatment group 
d p < 0.01 comparing S- warfarin with R- warfarin in rutin treatment group  
e p < 0.05 comparing S- warfarin with R- warfarin in rutin treatment group 
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rutin treatment is represented by Fig. 4.4 (a,b). The mean PCA values between the 
two treatment groups were similar before starting warfarin treatment and also before 
the 1st dose of rutin. With rutin treatment, the values appear to be higher from 72 h 
compared to control group levels. The difference was statistically significant at 72 h 
time point (p < 0.01). The average PCAmin values observed with rutin treatment group 
was 42.55 ± 11.95 and significantly higher (p < 0.01) when compared to that of 
control group (19.15 ± 5.96) (Table 4.3). 
 
4.4.3. Effect of rutin treatment alone on blood coagulation  
 
Effect of rutin treatment in the absence of warfarin on blood coagulation in rats is 
shown in Fig. 4.5 (a,b). The mean PCA values (as percentage of normal activity) were 
compared at different intervals over 168 h after the first dose of rutin. The time course 
of animals treated with rutin (1 g/kg/day) for 5 days showed no significant difference 
in mean PCA levels compared to the control rats that received only oral CM-cellulose 
for the same period. The average PT0 (± SD) of rutin treated and control groups were 




Warfarin is used widely around the globe for the treatment and prevention of 
thromboembolic diseases. It is generally administered orally in long-term therapy and 
its low cost makes it more suitable for chronic dosing regimen. In spite of 
accumulating evidence over the years of its excellent therapeutic benefits, the usage is 







































Figure 4.4  Changes in (a) prothrombin time (PT), (s) and (b) prothrombin complex 
activity (PCA), (percent of normal) with time following multiple doses of warfarin 
(0.15 mg/kg body weight) in control and rutin (1 g/kg body weight) treated rats. 
Animals from both the groups received oral racemic warfarin daily, for initial five 
days (blood samples were not collected/analyzed during this period). From “0” h, 
along with warfarin, control rats were given daily CM-cellulose (1% w/v) (5 ml/kg) 
and treatment group received rutin (1 g in 1 % CM-cellulose/kg) (5 ml/kg body 
weight, orally for 96 h.  
Values are expressed as mean ± S.D (n = 6).  
 
* p < 0.01 comparing the control group with rutin treatment group. 
 77
Table 4.3  Pharmacodynamic parameters of control (treated with CM-cellulose 
only) and rutin treated (rutin in CM-cellulose) rats after treatment with multiple doses 
of racemic warfarin (0.15 mg/kg body weight/day) orally.  
 
Parameter Control Rutin treated 
PT0 (s) 36.68 ± 5.57 38.35 ± 4.42 
 
PCAmin (% normal) 19.15 ± 5.96 42.55 ± 11.95 a 
 
Note: values are mean ± S.D. (n = 6) 
PT0, basal prothrombin time at time zero; PCAmin, minimum prothrombin complex 
activity;  
 





































Figure 4.5  Changes in prothrombin time (a) (PT), (s) and (b) prothrombin complex 
activity (PCA), (percent of normal) with time in rats treated with and without 
(control) rutin (1 g/kg body weight), daily from 0 to 96 h. Values are expressed as 
mean ± S.D (n = 6). There was no statistically significant difference in both PT and 
PCA values between the control and rutin treatment groups. 
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potential interactions leading to fatal bleeding (8). The management of warfarin 
anticoagulation is especially difficult in the elderly and those with co-morbid 
conditions and those who need concomitant treatment with other drugs (8). Warfarin 
with its narrow therapeutic window, can lead to serious hemorrhagic conditions when 
an interacting drug is added to an ongoing, long term, multiple dosing regimen of 
warfarin (119). Thus it is important to evaluate the potential interactions of multiple 
doses of warfarin and a longer treatment regimen in addition to single dose-warfarin 
study. 
 
Rutin is widely used in complementary and alternative medicines and numerous 
health supplements. Rutin has been reported to counteract dicoumarol in rats (107). 
When coadministered with warfarin, rutin is reported to be beneficial in patients with 
severe critical leg ischemia (23). Thus the two drugs together have a promising 
clinical application. But the potential for drug interaction needs to be carefully 
evaluated. Our study with single dose warfarin and rutin coadministration has shown 
some evidence of pharmacokinetic interactions between the two in rats. Hence in vivo 
multiple dose warfarin-rutin interaction study was designed. 
 
Rats were treated with warfarin orally for five days before co-administering warfarin 
and rutin daily for subsequent five days. This could possibly mimic a clinical case of 
patient stabilized on warfarin therapy taking a rutin supplement or diet rich in rutin. 
Lower dose of warfarin (0.15 mg/kg/day) was selected to avoid fatalities in animals. 
The rats were monitored closely throughout the study and all the animals were found 
to tolerate the long treatment regimen and the repeated blood sampling well. 
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Consistent with literature reports that R-warfarin is eliminated faster in rats and 
slower in man compared to S-warfarin elimination kinetics (48, 110), higher clearance 
and shorter elimination half-life for R-warfarin, in comparison to S-warfarin, were 
observed in control rats. This was observed earlier in our single dose study as well. t1/2 
values of multiple dose study were similar to that of single dose study for both the 
enantiomers. It is known that the PK parameters do not vary much between single 
dose and multiple doses of the drug assuming that the absorption is very fast.   
 
Pharmacokinetic parameters of S- and R-warfarin also showed a trend of interaction 
in the presence of rutin similar to single dose study. The serum levels of both the 
enantiomers in rutin treated rats were lower compared to that in control group. S-
warfarin levels significantly differed between the two groups at 72 and 96 h time-
points. R-warfarin levels also showed a decline with rutin treatment. The steady state 
serum clearance of S- warfarin tended to be higher in the rutin-treated group though 
the value showed no statistically significant difference when compared to the control 
group. There was an apparent lowering of steady state volume of distribution of S- 
warfarin compared to that of control group. Hence, shorter elimination half-life value 
of S- warfarin was observed with rutin treated rats compared to that of control. This in 
turn could have been responsible for the observed lower levels of S- warfarin and 
possibly the faster recovery of PT with rutin treatment, similar to single dose study. 
The steady state volume of distribution and clearance of R- warfarin showed no 
difference with rutin treatment and the elimination half-life value showed no change 
compared to control values. Elimination half-life of S- warfarin is shorter compared to 
that of R- Warfarin with rutin treatment though.  
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Quercetin was recently reported to inhibit both CYP2C9 and CYP3A4 significantly in 
human liver microsomes (6). This should correspond to increased serum levels of 
both S- and R- warfarin and reduced clearance value. But in our study of both single 
and multiple warfarin doses, rutin treatment appeared to reduce the levels of S- 
warfarin with apparent increase in clearance and shorter elimination half-life. Volume 
of distribution and clearance are two independent pharmacokinetic variables that can 
affect the elimination half-life of a drug (t1/2 α V/CL). Depending on various 
physiological conditions like disease states, blood flow to the liver, intrinsic 
clearance, or protein binding, alteration of one or more of these factors can have a 
significant effect on the t1/2 of the drug (123). When the clearance of the drug is 
slightly increased or unchanged, decrease in volume of distribution (possibly due to 
an increased plasma protein binding) can result in shorter elimination half-life. This 
could possibly explain the correlation between the increase in clearance and reduction 
in volume of distribution and the elimination half life of S- warfarin with rutin 
treatment in our study.  
 
Warfarin is eliminated mainly by liver but it is a low hepatic extraction ratio drug 
(124). For low hepatic extraction ratio drugs, hepatic clearance (CLh) is dependent on 
unbound fraction of the drug (fu) and intrinsic clearance (CLint) of the liver (CLh = 
fu.CLint). Increase in the intrinsic clearance of the liver can lead to increased hepatic 
clearance of warfarin. As the steady state drug concentration is inversely proportional 
to the clearance, the lowering of S-warfarin steady state concentration as seen in our 
study could possibly be due to a change in the intrinsic clearance or tissue unbound 
fraction. Moreover, various research works have shown that the data obtained from in 
vitro and in vivo work with respect to cytochrome P450 modulation do not always 
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correlate. Similar to the contradiction between our study and in vitro data on 
quercetin, the antiemetic drug Aprepitant (neurokinin-1 receptor antagonist) was 
reported to inhibit CYP3A4 when incubated with human liver microsomes in vitro 
(113), and in human subjects (in vivo) using midazolam as a probe substrate of 
CYP3A4 (114). But it was shown to have a modest inductive effect on both CYP3A4 
and CYP2C9 in vivo using midazolam and tolbutamide as a probe substrate 
respectively (116). Aprepitant also induced S- warfarin metabolism in healthy 
subjects indicating an induction of CYP2C9 (115). Although due to various 
constraints the present study could not include interaction studies using specific 
hepatic microsomes, such in vitro studies in the future may help to understand this 
aspect of the interaction better.     
 
Both warfarin and quercetin bind to the IIA domain of albumin (117, 118) and 
quercetin is shown to be displaced by large excess of warfarin, although not 
competitively (24, 94). In our study there was a trend to reduce the volume of 
distribution of S- Warfarin. At this point of the study, it is difficult to conclusively 
explain the observed interactions in various pharmacokinetic parameters. Further 
analysis of the warfarin metabolites in urine and the protein binding studies may help 
in understanding this potential interaction better. However the results so far clearly 
show the potential trend of interaction between rutin and warfarin both in single and 
multiple doses.  
 
There was no significant difference in mean PT values between the rutin treatment 
and control groups prior to rutin dosing (PT0). The results obtained with rutin 
treatment were similar to single dose study with respect to anticoagulation. The 
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degree of hypoprothrombinaemic response was reduced at all time-points with 
concurrent rutin administration compared to warfarin alone group. The higher levels 
of PCA and average PCAmin obtained indicated overall reduction in the 
anticoagulation response to warfarin. The difference in PCA between the two groups 
was especially significant at 72 h time point (p < 0.01). The lower serum levels of S- 
warfarin observed with rutin treatment compared to that in control rats provides an 
explanation for this effect of rutin on anticoagulation.  
 
Rutin is reported to be well tolerated in rats when administered at a high dose for a 
long time (97). But there was no information on its effect on clotting time. Thus we 
further evaluated the effect of rutin on coagulation process in rats compared to that in 
control animals. The study was designed to determine the effects of rutin on blood 
coagulation in the absence of warfarin. The results indicated that rutin by itself had no 
effect on PT (PCA) and ruled out the possibility of rutin affecting coagulability 
directly. Rutin treatment alone showed no significant effect on blood coagulation 
compared to that of control. When administered with warfarin, the observed changes 




The results showed the potential interaction between rutin and multiple doses of 
warfarin. S- warfarin levels in serum were reduced and the PCA values increased with 
co-administration of rutin. PK parameters also varied between the control and rutin 
treated groups. The S- warfarin steady state clearance increased and volume of 
distribution and elimination half-life reduced with rutin treatment. The results were 
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similar to single dose study. The 2nd part of the study reveals that rutin by itself does 
not affect the blood coagulation and clotting process. Given at high doses, rutin 
treatment showed no significant difference compared to CM-cellulose treatment in PT 
and PCA values and the animals well tolerated the drug throughout the study period.  
 
Thus the possible interactions should be carefully considered when a patient stable on 
warfarin treatment starts taking flavonoid (rutin) rich diet or health supplements. 
Studies have shown that many of the patients on warfarin therapy also self-medicate 
with alternative medicines (76). As warfarin has a narrow therapeutic window, the 
maintenance of coagulation within desirable range is critical and so is avoiding 




CHAPTER 5  CONCLUSION 
 
The potential drug interaction between rutin, a flavonoid glycoside and warfarin, the 
oral anticoagulant, was investigated in rats. The study was designed to estimate the 
effects of both single and multiple oral doses of racemic warfarin in rats treated with 
rutin. The results reveal a possible pharmacokinetic drug interaction between rutin 
and oral warfarin in both the studies. 
 
Rutin treatment along with single dose of warfarin increased the Cmax and reduced the 
t1/2 and Vd values of both S- and R- warfarin significantly and lowered the serum 
levels of both the enantiomers in the elimination phase compared to the control group. 
Rutin treatment also increased the total area under the PCA-time curve from 0 to 96 h 
post warfarin indicating an overall reduction in the anticoagulation response to 
warfarin. Recovery from warfarin anticoagulation was found to be much faster in the 
presence of rutin. 
 
With multiple doses of warfarin, rutin treatment resulted in lower serum levels of S- 
warfarin, higher PCA values and lower anticoagulation compared to control. Of S- 
warfarin, the clearance was increased, and the volume of distribution and elimination 
half-life reduced compared to corresponding control values. Also, rutin by itself did 
not affect the blood coagulation and clotting process. 
 
Thus the potential interactions should be carefully evaluated when rutin and warfarin 
are coadministered. Extra care must be taken when a patient stable on warfarin 
treatment starts taking flavonoid (rutin) rich diet or health supplements or when high 
 86
levels of rutin aglycone and conjugates are present in patient blood before starting 
warfarin therapy. Furthermore, if the patient has been stabilized on warfarin with 
concomitant use of rutin or quercetin, precaution should be taken to avoid sudden 
suspension of rutin.  
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CHAPTER 6  POTENTIAL APPLICATIONS AND SUGGESTIONS 
FOR FUTURE WORK 
 
6.1. POTENTIAL APPLICATIONS  
 
Understanding the mechanism involved in a drug interaction can help to make better 
prediction of the potential interaction. Ability to quantitatively measure the interaction 
is crucial in this scenario. When the mechanism of the interaction is well understood 
and is both predictable and quantifiable, then we can weigh the benefits of such 
combinations of drugs more judiciously.  
 
Warning both medical professionals and patients about the potential for interaction 
between complementary medicines and prescribed drugs may reduce the risk of some 
of the life threatening interactions. It is all the more important, considering the benign 
nature and prevalent use of herbal alternative medicines and for drugs with narrow 
therapeutic indices like warfarin. Although patients treated with warfarin are usually 
counseled for possible interactions with herbal medicines, noncompliance (use of 
herbal products or failure to follow the advice) can result in loss of anticoagulation 
and fatal bleeding. Also the composition of health food often differs among different 
brands and manufacturers. Thus proper evaluation and a detailed case history of all 
the drugs and alternative medicines taken should be carried out in patients with 
unstable anticoagulation state.   
 
The results of the present study indicate a potential interaction between rutin and 
warfarin. As rutin and its aglycone – quercetin, are present in numerous diets of plant 
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origin, precaution must be taken when rutin and warfarin are coadministered. 
Interactions should be carefully considered when either rutin or warfarin treatment is 
initiated or suspended in a patient with high levels of either of them in blood. 
Therapeutic monitoring of warfarin is useful in this condition and warfarin dose 
should be adjusted accordingly.  
 
6.2. SUGGESTIONS FOR FUTURE WORK 
 
Although the present study indicates a potential interaction between warfarin and 
rutin, actual mechanisms of the interactions need to be evaluated further. Studies on 
the effect of rutin/quercetin on S- and R-warfarin metabolic profiles in urine, specific 
hepatic enzymes in vitro, and protein binding could give more insight into the 
potential interactions and the basis for underlying mechanisms. 
 
Quercetin has been reported to bind strongly to human serum albumin in vitro (24) as 
well as rodent albumin (14). Both warfarin and quercetin bind to the IIA domain of 
albumin (117, 118) and quercetin is shown to be displaced by large excess of 
warfarin, although not competitively (24, 94). In the present study, as total serum 
clearance was not altered much, rutin administered in large excess could have affected 
the serum and tissue protein binding of warfarin. Analysis of protein and tissue 
binding should be carried out to understand the mechanisms of this interaction. 
 
Quercetin is reported to inhibit the activity of carbonyl reductases in vitro (90), 
CYP1A2 (91) and both CYP2C9 and CYP3A4 in human liver microsomes (6). 
Quercetin is also reported to increase the expression of CYP1A1 (82). Thus it can 
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potentially affect the metabolism of warfarin. However, in our study S- warfarin 
levels were reduced with rutin treatment. Such discrepancies between in vitro and in 
vivo data have been reported in various other studies as well (113, 114, 115, 116, 
125). Nonetheless, in vitro studies using specific CYP enzymes may shed more light 
on this interaction and the data needs to be carefully evaluated to scale upto clinical 
interactions. 
 
Warfarin is extensively metabolized in the liver, with only 2-5 % of the dose present 
unchanged in urine in human and 5-9 % in rat urine (126, 127). As warfarin 
enantiomers and the metabolites are predominantly excreted by kidney, detailed 
estimation of warfarin metabolites in urine is useful to understand the extent to which 
warfarin metabolism and excretion are affected. It can provide valuable insight into 
the metabolism and clearance of warfarin enantiomers and potential metabolic 
interactions with rutin, if any. Modeling of the serum and urine data together with 
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